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V. Summary 
 
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive interstitial lung 
disease characterized by abnormal and excessive deposition of fibrotic tissue in the 
pulmonary interstitium. Elevated procoagulant and decreased fibrinolytic activities have 
been observed in bronchoalveolar lavage (BAL) fluid from IPF patients. Alterations of 
alveolar haemostatic balance, mainly due to increased expression of tissue factor (TF), 
factor VII (FVII) and plasminogen activator inhibitor 1 (PAI-1), and decreased synthesis 
of urokinase (u-PA) promote fibrin deposition in the alveolar compartment. Moreover, 
cellular activities of coagulation factors also potentiate fibrotic responses in the lungs 
through stimulation of fibroblast proliferation and differentiation, production of 
profibrotic cytokines and increased deposition of extracellular matrix components.  
Coagulation factor XII (FXII) is a key component of the intrinsic blood coagulation 
pathway involved in coagulation, fibrinolysis and inflammation. Active FXII (FXIIa) 
converts factor XI (FXI) into activated FXI (FXIa) and prekallikrein (PK) into kallikrein 
(KLK). Consequently, FXI activation culminates in a series of proteolytic reactions 
resulting in thrombin generation and the release of the proinflammatory and vasodilatory 
bradykinin (BK). 
The implication of the extrinsic coagulation pathway in the pathogenesis of 
pulmonary fibrosis has been well described, however the potential role of intrinsic 
coagulation factors, namely FXII, FXI and high molecular weight kininogen (HMWK), 
has never been reported in the pathomechanisms of chronic fibroproliferative lung 
diseases. The present study was undertaken to evaluate the contribution of the intrinsic 
coagulation pathway in the pathogenesis of IPF. 
Increased expression of FXII, FXI and HMWK and elevated activity of FXIIa were 
detected in the lungs of bleomycin-treated mice as well as of IPF patients. The strongest 
immunoreactivity of FXII was observed in fibroblasts and on the surface of alveolar 
epithelial type II cells (ATII). In vitro experiments identified FXIIa as a potent mitogen 
for primary murine lung fibroblasts. FXIIa mitogenic activity was mediated by the α51-
integrin and the u-PA receptor (uPAR), since a blockade of these molecules abolished 
FXIIa-induced cell proliferation. Moreover, FXII-dependent induction of lung fibroblast 
proliferation was attenuated by the pharmacological blockade of the extracellular signal-
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regulated kinase (ERK) 1/2 pathway. In line with in vitro data, FXII knockout mice were 
found to be protected against bleomycin-induced fibrosis and intratracheal application of 
FXIIa inhibitor strongly reduced a fibrotic response after bleomycin administration. The 
lack in reduction of fibrotic responses in bradykinin receptor 1/2 deficient mice indicated 
that BK did not mediate FXII profibrotic properties.  
Although regulation of FXII expression by estrogen in hepatocytes is well 
described, no data are available about regulation of FXII synthesis in cells other than 
hepatocytes. Interestingly, human lung fibroblasts (HLF) were found to express FXII in a 
regulated manner. Treatment of HLF with Transforming growth factor-β1 (TGF-β1) 
induced FXII production in a time-dependent manner. The intracellular mechanism by 
which TGF-1 stimulates FXII expression was investigated and the respective FXII 
promoter region necessary for TGF-1 mediated FXII production was characterized.  
In conclusion, these findings identified FXII/FXIIa, apart from its possible role as 
coagulation factor in the alveolar compartment, as a novel profibrotic factor that may 
contribute to the development of lung fibrosis by potentiating proliferation of lung 
fibroblasts. Therefore, FXII and its downstream signaling pathway in lung fibroblasts 
should be considered as a novel target for therapeutic intervention in pulmonary fibrosis. 
Zusammenfassung  
________________________________________________________________________ 
VI. Zusammenfassung 
 
Die idiopathische Lungenfibrose (IPF) ist eine seltene, chronisch progressiv 
verlaufende, interstitielle Lungenerkrankung, die durch übermäßige Deposition von 
fibrotischem Gewebe im Interstitium charakterisiert ist. In der bronchoalveolären 
Lavageflüssigkeit von IPF Patienten finden sich erhöhte prokoagulatorische und 
erniedrigte fibrinolytische Aktivitäten. Veränderungen der alveolaren Homöostase, 
hauptsächlich verursacht durch vermehrte Expression von Gewebsfaktor (Tissue factor, 
TF), Faktor VII und Plasminogen Aktivator Inhibitor 1 (PAI-1), sowie verminderte 
Synthese von Urokinase (u-PA), verstärken die Fibrinablagerungen in den Alveolen. 
Zusätzlich steigern die Gerinnungsfaktoren die fibrotische Reaktion der Lunge durch 
Stimulation der Dedifferenzierung und Proliferation von Fibroblasten, Produktion von 
pro-fibrotischen Zytokinen und extrazellulären Matrixkomponenten. 
Gerinnungsfaktor XII (FXII) spielt eine Schlüsselrolle in der intrinsischen 
Gerinnungskaskade während der Koagulation, Fibrinolyse und Inflammation. FXIIa 
aktiviert Faktor XI (FXI) zu Faktor XIa (FXIa) und Prekallikrein (PK) zu Kallikrein 
(KLK). In der Folge kommt es zu einer Serie von proteolytischen Reaktionen, die zur 
Synthese von Thrombin und zur Freisetzung des proinflammatorisch und vasodilatorisch 
wirkenden Bradykinins (BK) führen. 
Die Bedeutung des extrinsischen Gerinnungssystems für die Pathogenese der 
Lungenfibrose ist relativ gut erforscht. Eine potentielle Rolle für intrinsische 
Gerinnungsfaktoren, wie FXII, FXI und hochmolekulares Kininogen (HMWK), wurde 
dagegen noch nicht im Hinblick auf den Pathomechanismus chronisch fibroproliferativer 
Lungenerkrankungen untersucht. Ziel dieser Arbeit war daher die Evaluation der 
Bedeutung des intrinsischen Gerinnungssystems für die Pathogenese der IPF.  
Sowohl in den Lungen Bleomycin-behandelter Mäuse als auch von IPF Patienten 
war die Expression von FXII, FXI und HMWK, sowie die Aktivität von FXII erhöht. Die 
stärkste Reaktivität von FXII fand sich in Fibroblasten und an der Oberfläche von 
Alveolarepithelzellen vom Typ II (ATII). In vitro Experimente identifizierten FXIIa als 
potentes Mitogen für primäre murine Lungenfibroblasten. Da die Inhibierung von α5β1-
Integrin und dem Urokinaserezeptor (uPAR) ausreichte, um die FXII-vermittelte 
Proliferation von Fibroblasten aufzuheben, konnten diese Moleküle als übergeordnete 
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Mediatoren identifiziert werden. Daneben konnte auch eine pharmakologische 
Inhibierung des extracellular signal-regulated kinase (ERK) 1/2 Signalweges die FXII-
abhängige Proliferation pulmonaler Fibroblasten hemmen. 
In Übereinstimmung mit den in vitro Daten, waren FXII Knockout-Mäuse 
geschützt gegen eine Bleomycin-induzierte Fibrose. Daneben konnte auch eine 
intratracheale Applikation von FXIIa Inhibitor in Bleomycin-behandelten Mäusen die 
fibrotische Reaktion signifikant hemmen. Da bei Bradykininrezeptor 1/2-defizienten 
Mäusen keine Verringerung der fibrotischen Reaktion auftrat, scheint FXII auf diesem 
Weg keine Wirkung zu entfalten. 
Während in Hepatozyten die Regulation der FXII Expression durch Östrogen 
beschrieben ist, gibt es zurzeit keine Daten für andere Zelltypen. Interessanterweise 
exprimieren humane Lungenfibroblasten (HLF) FXII, weshalb hier die Regulation der 
FXII Expression genauer untersucht wurde. Die Behandlung von HLF mit TGF-β1 führte 
dabei zu einem zeitabhängigen Anstieg der Expression von FXII. Durch weitere 
Untersuchungen zum intrazellulären Mechanismus konnten die spezifischen Stellen in 
der Promoterregion charakterisiert werden. 
Zusammengefasst identifizieren diese Ergebnisse FXIIa als neuen pro-fibrotischen 
Faktor, der, unabhängig von seiner möglichen Gerinnungsaktivität im Alveolarraum, über 
eine verstärkte Proliferation von Lungenfibroblasten entscheidend zur Entstehung der 
Lungenfibrose beiträgt. Daher bieten sich FXII und seine nachgeschalteten Signalwege 
als neue Angriffspunkte in der Therapie der Lungenfibrose an. 
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1. Introduction 
 
1.1. Blood Coagulation Pathways 
 
Blood coagulation is a defense mechanism which prevents blood loss from 
damaged vessels. One can distinguish two pathways of blood coagulation: intrinsic and 
extrinsic. Extrinsic pathway activation takes place when TF is exposed to plasma during 
vessel injury. TF is a non-enzymatic lipoprotein expressed on the surface of cells that 
normally have no contact with plasma. The interaction of TF with FVIIa, which circulates 
in plasma, triggers the activation of Factor X (FX). This leads to conversion of 
prothrombin to thrombin, followed by fibrin formation.  
The intrinsic coagulation pathway can be triggered in vitro when blood has contact 
with negatively charged surfaces like kaolin (1), sulfatides (2), dextran sulfates, 
phospholipids, urate crystals and glass (3). It is believed that the activation of this 
pathway occurs when FXII binds to artificial surfaces and autoactivates. FXII can be also 
activated by KLK (4,5). Activation of FXII is enhanced by HMWK, which serves as a 
docking protein (6). Activated FXII triggers the activation of FXI, followed by FXa 
generation and thrombin formation (Figure 1.1).  
  
1.1.1. Structural and functional characteristics of the intrinsic 
coagulation pathway factors 
 
1.1.1.1. Factor XII 
 
FXII is produced in the liver as a single chain 78 kD zymogen. Activated FXII 
consists of a heavy and a light chain (7). The heavy chain contains the following 
domains: leader peptide, fibronectin type II domain, the epidermal growth factor (EGF) 
domain, fibronectin type I domain, the kringle domain, and the proline reach domain, 
which is unique for FXII (Figure 1.2) (8). FXII has a similar domain organization as the 
serine protease family members tissue-type plasminogen activator (t-PA) and u-PA, but is 
different from other coagulation factors (8). The heavy chain contains artificial surface 
binding regions localized at the amino terminus, fibronectin type I region (9), and 
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possibly localized at the second EGF-like domain or kringle domain (10). The light chain 
contains the catalytic domain typical for serine proteases. The active site of FXII consists 
of canonical His40, Asp89 and Ser191 residues (8,11). This site is also a target for the 
major intrinsic coagulation pathway inhibitor, C1 inhibitor (12). Cleavage of FXII by 
KLK or its autoactivation results in the splitting of the Arg353-Val354 bound in the FXII 
zymogen, leading to the generation of the active alphaXIIa form, which contains a heavy 
and a light chain bound by a disulfide bond (11). Hydrolysis of two more peptide bonds 
in alphaXIIa form generates 30 kDa betaXIIa, which consists of a light chain and a small 
fragment of a heavy chain. AlphaXIIa is able to bind to negatively charged surfaces and 
activates FXI and PK. BetaXIIa has no surface-binding ability but can activate PK (13).  
 
 
 Extrinsic coagulation 
pathway 
Intrinsic coagulation pathway 
 
 
Figure 1.1. Blood coagulation pathways. 
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FXII 
FXI 
Prekallikrein 
Fibronectin type II domain EGF-like domain
Kringle  domain Repeat sequences 
Fibronectin type I 
domain Catalytic domain
Activation cleavage site  
Figure 1.2. Structure of intrinsic coagulation pathway protease zymogens. 
 
1.1.1.2. Factor XI 
 
FXI is synthesized in the liver as a glycoprotein with a molecular weight of 143 kDa 
(14). This serine protease consists of two identical peptide chains bound by disulfide 
bonds and therefore contains two active sites. Each of the two peptide chains consists of a 
heavy and a light chain, which are connected to each other by disulfide bonds. Each light 
chain contains an active site, which consists of His44, Asp93, and Ser188 . FXI domains 
are homologous to domains of PK (Figure 1.2) (14). FXI is activated by FXII in the 
presence of HMWK after cleavage of the disulfide bond in each polypeptide chain 
(15,16). Activated FXI cleaves further FIX. Inherited FXI deficiency, also called 
Hemophilia C, is an uncommon autosomal recessive disorder, which is associated with a 
variable bleeding tendency that usually occurs after trauma or surgery (17). There are 
reports showing that FXI may be activated independently of FXII, by thrombin (18). In 
view of opposing results (19) it is still questionable, whether thrombin activates FXI in 
vivo.  
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1.1.1.3. High molecular weight kininogen 
 
There are two forms of plasma kininogens, HMWK and low molecular weight 
kininogen (LMWK). Both molecules are the products of the same gene (20,21). HMWK 
is mainly synthesized in the liver as a 120 kDa glycoprotein (20). Moreover, HMWK was 
found in human umbilical vein endothelial cells (22), primary fetal murine fibroblasts, 
human fibroblast cell line WI-38 (23,24), platelets (23), granulocytes (24), renal tubular 
cells (25,26), and skin (27).  
The single polypeptide chain of HMWK consists of a heavy chain (domains 1-4), a 
BK region (domain 4) and a light chain (domain 5-6) (28). Each domain of HMWK 
possesses physiological activities. Domain 1, with unclear function, contains Ca2+-
binding site (29). Domains 2 and 3 contain highly conserved pentapeptide QVVAG, 
responsible for cysteine protease inhibitory activities of HMWK (30,31). Domains 3 and 
5 bind in a Zn2+ dependent manner to thrombocytes (32,33), neutrophils (34,35) and 
endothelial cells (38,39). HMWK bound to thrombocytes inhibits thrombocytic calpain, 
attenuating  binding of thrombin and subsequent aggregation of thrombocytes. HMWK 
acts as an anti-adhesive molecule after binding to multinuclear leucocytes (MNL) (36). 
HMWK is also required for the KLK stimulated activation of MNL (37). Domain 4 
contains BK sequence. BK delivery is the major activity of HMWK. The cleavage of 
HMWK by plasma KLK leads to generation of BK and kinin free protein (HMWKa) 
(20,21). HMWKa consists of a 62 kDa heavy and a 56 kDa light chain. The functions of 
BK will be described later.  
The light chain of HMWK is involved in binding to hydrophilic and anionic 
surfaces and contains regions binding PK and FXI (38). Thus HMWK has the ability to 
mediate interactions between FXII, FXI and PK and the vascular wall (39). Therefore, 
HMWK as a nonenzymatic cofactor is involved in the forming a complex and is involved 
in the activation of intrinsic coagulation pathway protease zymogens. HMWKa has been 
reported to induce apoptosis of proliferating endothelial cells and to inhibit angiogenesis 
(40,41). Domain 5 inhibits endothelial cell migration towards vitronectin (42). There are 
reports suggesting that HMWKa inhibits endothelial cells adhesion on vitronectin (42-
44).  
 
 4
Introduction  
________________________________________________________________________ 
 
1.1.1.4. Kallikrein 
 
PK is a glycoprotein produced as a zymogen in hepatocytes (45). The amino acid 
sequence has a high homology to FXI (46). PK circulates in plasma in a complex with 
HMWK (47) and has a molecular weight of 85 kDa or 88 kDa (45). Two forms of FXII 
(alphaXIIa and betaXIIa) have the ability to activate PK (48). Cleavage of PK generates 
KLK (Figure 1.3) which consists of a heavy and a light chain bound by a disulfide bond. 
The light chain contains an active site, which consists of His, Asp and Ser residues (49). 
The heavy chain is responsible for the binding of HMWK and FXII (50). On the 
endothelial cell surface, activation of KLK occurs in the absence of FXII (6,51). C1 
inhibitor has been recognized to be a major inhibitor of KLK (52-54). α2-Macroglobulin 
is also able to bind and block KLK activity, although to a much lesser extent (55). KLK 
has many bioregulatory functions. KLK activates u-PA potentiating fibrinolysis on the 
surface of endothelial cells. Moreover, KLK is able to activate prorenin (56,57) and FXII 
(4). Purified KLK has been shown to aggregate human blood neutrophils (58,59).  
The major role of KLK is cleavage of HMWK and delivery of BK, which has 
various physiological activities (Figure 1.3). BK is a peptide with vasodilatory and 
proinflammatory properties. BK stimulates synthesis of prostacyclin by endothelial cells, 
thereby inhibiting platelets and inducing vasodilation through elevation of intracellular 
cAMP level. It induces nitric oxide (NO) synthesis in endothelial cells, which acts as a 
vasodilator, inhibitor of platelet function and smooth muscle cell proliferation. BK is the 
strongest stimulator of t-PA release. Thus, BK generation plays a crucial role in the 
regulation of arterial pressure, modulation of vascular function and is responsible for 
classical signs of inflammation: redness, local heat, swelling, and pain. BK acts through 
two G-protein-coupled receptors: B1 and B2 (60). The B2 receptor is broadly and 
constitutively expressed, whereas the B1 receptor is weakly expressed under basal 
conditions but becomes upregulated during inflammation. Both receptors play important 
roles during inflammation and injury (61).  
BK can also be generated in FXII independent manner by tissue kallikreins (62,63). 
Nevertheless, FXII is important for the proper rate of KLK generation and the release of 
BK and HKa, since in FXII deficient mice the plasma level of BK is supressed (64). 
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Figure 1.3. The KLK/kinin system.  
 
1.1.2. Activation of FXII 
 
1.1.2.1. Contact activation of FXII 
 
FXII may be activated either by autoactivation on a negatively charged surface or 
by KLK. Many negatively charged physiological surfaces upon which FXII autoactivates 
have been described: articular cartilage, skin, fatty acids (65), endotoxin (66), amyloid 
protein (67), RNA (68), dextran sulfate, acidic phospholipids (69), sulfatides, 
glycocerebroside sulfates (2,70) and collagen (71).  
Activation of platelets has been reported to promote fibrin generation in a FXII-
dependent manner (72,73). A recent study has shown that polyphosphates (PolyP), 
secreted upon platelet activation, bound to and activated FXII in vivo (74). PolyP-
activated FXII triggered not only plasma clotting, but also generation of proinflammatory 
BK. There are studies suggesting that acidic phospholipids and sulfatides expressed in 
platelets may activate FXII in vivo (69,75). It is worth mentioning that binding to and 
autoactivation of FXII on sulfatides has been reported to be Zn2+ independent, whereas 
autoactivation on other negatively charged substances has been demonstrated to be Zn2+ 
dependent (76-78). The activation of FXII in vivo may also be promoted by nucleic acids 
derived from damaged cells (68). Furthermore, it has been reported that misfolded protein 
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aggregates produced during systemic amyloidosis trigger FXII activation which results in 
KLK/kinin system activation without induction of the coagulation cascade (67). 
 
1.1.2.2. Activation of the contact system on the endothelial cell surface 
 
There are four components of the contact system: FXII, FXI, PK and HMWK. In 
vitro, FXII binds to negatively charged surfaces and undergoes autoactivation. Activated 
FXII cleaves PK into KLK (79). It has been shown that HMWK, FXII and PK can bind to 
cultured endothelial cells, platelets and granulocytes in a Zn2+ dependent manner. The 
specific binding sites for HMWK and FXII have been identified (6). Putative receptors of 
HMWK and FXII on endothelial cells are first complement component (C1q) receptor 
(gC1qR), uPAR and cytokeratin 1 (CK1). FXII and HMWK compete for the same 
binding sites on the endothelial cell surface (80-83). HMWK mediates binding of PK and 
FXI to the cell surface. PK binding sites other than HMWK have not yet been identified 
(6). FXI in contrast to PK has the ability to directly bind to platelets (84).  
FXII binding to endothelial cells requires a much higher concentration of Zn2+ than 
a binding of HMWK/PK complex. Moreover, FXII is not activated on the endothelial cell 
surface in the absence of PK in plasma (6,51). These data suggest that FXII activation on 
endothelial cells follows PK assembly and activation. Assembly of contact phase proteins 
on the endothelial cell membrane leads to the formation of a multiprotein complex, that 
leads to PK activation by endothelial cell cysteine protease independent of FXII (83,85). 
PK activator on the endothelial cell surface has been identified to be a 
polycarboxypeptidase (PCRP) (85). Active KLK can further activate FXII into FXIIa.  
 
1.1.2.3. Inhibition of FXII activity  
 
1.1.2.3.1. Inhibition of FXII activity in vitro 
 
Since FXII autoactivation occurs on negatively charged surfaces such as 
polyphosphates (74) and nucleic acids (68), phosphatases, RNases and DNases 
respectively, may be considered as possible FXII activation blockers. A specific Zn2+ 
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chelator could be another possible tool to control phospholipid-mediated FXII activation. 
Several native bioactive substances have been identified as FXIIa inhibitors.  
Corn trypsin inhibitor (CTI) derived from corn seeds specifically inhibits FXIIa. It 
appears to inhibit only FXIIa among enzymes of the blood coagulation system (86,87). It 
is a 12 kDa polypeptide with no sequence similarity to other serine protease inhibitors 
(88). The exact mechanism of FXIIa inhibition by CTI is not clear. CTI was shown to 
bind to the precursor and activated forms of FXII (87,89). Most likely CTI binds 
reversibly to FXIIa and inhibits its activity by changing the conformation of FXIIa (87). 
CTI was also reported to block mitogenic activities of FXIIa (90,91).  
Another FXIIa inhibitor isolated from pumpkin seeds (Pumpkin seed Hageman 
factor inhibitor) is a 3 kDa polypeptide. It also weakly inhibits human plasmin and bovine 
FXa (92). H-D-Pro-Phe-Arg-chloromethylketone (PCK) is the active-site directed 
inhibitor of activated FXII (93). It inhibits the amydolytic activity of FXIIa and plasma 
KLK-mediated activation of FXII (94).  
 
1.1.2.3.2. Inhibition of FXII activity in vivo 
 
C1 inhibitor is regarded as the most potent physiological FXII inhibitor, accounting 
for greater than 90% of the inhibition of this protease in plasma. C1 inhibitor binds 
irreversibly to alphaXIIa and betaXIIa (12,95). When associated with the kaolin surface, 
FXIIa is protected against inhibition by C1 inhibitor (96). FXII activity can also be 
attenuated, although to a lesser extent, by antithrombin (97), PAI-1 (98) and alpha 2- 
macroglobulin (99). 
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1.1.3. Physiologic activities of FXII  
 
1.1.3.1. FXII and inflammatory reactions  
 
1.1.3.1.1. FXII in hereditary angioedema 
 
FXII is involved in inflammatory reactions since it enhances the generation of BK 
from HMWK by activating PK (100). Consequently, active KLK enhances the rate of 
FXIIa formation by reciprocal activation (4). Hereditary angioedema (HAE) is 
characterized clinically by episodes of angioedema with increased vascular permeability, 
particularly by recurrent acute skin swelling, abdominal pain, and potentially life-
threatening laryngeal edema (101). Three forms of HAE have been described. The classic 
forms, HAE types I and II, are the consequence of mutations in the C1 inhibitor gene 
(102). The C1 inhibitor regulates the activity of both KLK (103) and FXII (99) by 
irreversible binding to these enzymes. Increased activity of FXII and KLK, due to the 
lack of inhibition by C1 inhibitor, leads to increased generation of BK, which results in 
increased vascular permeability and angioedema (102).  
In contrast to HAE types I and II, HAE type III, characterized by increased activity 
of FXII (104), has been observed exclusively in women, where it appears to correlate 
with high estrogen levels, for example, pregnancy or the use of oral contraceptives. These 
conditions are characterized by elevated FXIIa plasma level, probably due to estrogen-
induced FXII synthesis in hepatocytes.  
 
1.1.3.1.2. FXII in sepsis 
 
FXII and PK levels are low in sepsis, which may be a result of contact system 
activation on the bacterial surface followed by increased consumption of activated 
proteases (105). This can further lead to a release of BK, which promotes inflammation 
and a hypocoagulatory state (106). This mechanism may contribute to symptoms of 
sepsis like plasma leakage, hypotension and formation of microthrombi. FXIIa, through 
activation of the contact system, was shown to contribute to disease progression of severe 
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Salmonella lung infection in the mouse model. Accordingly, PCK, an inhibitor of FXIIa, 
was shown to prevent pulmonary lesions in mice infected with Salmonella (107).  
In vitro, FXIIa activates C1q (93), downregulates a monocyte Fc receptor (108) and 
releases IL-1 and IL-6 from monocytes and macrophages (109). Purified plasma FXIIa is 
able to aggregate human neutrophils and causes their degranulation (110). FXII has been 
shown to activate chimerin, which is a ubiquitous plasma chemoatractant (111). 
Activated chimerin directs plasmatoid dendritic cells and macrophages to sites of 
infection and inflammation (112). Thus, FXII absorption and activation on the bacterial 
surface may also contribute to the host’s defense system by regulating leucocyte function. 
 
1.1.3.2. Factor XII in thrombosis 
 
Deficiency of FXII, PK and HMWK is associated with no bleeding disorder. 
Therefore, the role of FXII in physiological haemostasis is not clear. All of these 
deficiencies are exceedingly rare. FXII deficiency is the most common one. Clinical 
investigations related to venous thrombosis risk or polymorphism of FXII and their 
influence on cardiovascular disease resulted in conflicting data. On the one hand, it has 
been postulated that there is an increased incidence of venous and arterial thrombosis in 
patients with FXII deficiency (113-115). Epidemiological studies showed that patients 
with a decreased FXII level have a greater risk of developing thrombotic disorders such 
as myocardial infarction and re-thrombosis of coronary arteries after thrombolytic therapy 
(116-118). On the other hand, the occasional venous thrombosis seen in patients with 
FXII deficiency seems to be due to other associated prothrombotic risk factors (119) and 
hypercholesterolemia (120). Finally, the most recent data indicates no correlation 
between FXII deficiency and an increased risk of thrombosis (121-124).  
To elucidate FXII functions in vivo FXII knockout (FXII-/-) mice were generated 
(125). FXII-/- mice are healthy and fertile and do not suffer from pathologic bleeding 
despite having prolonged activated partial thromboplastin time (125). FXII deficient mice 
have reduced arterial thrombosis risk in a mouse model of lethal pulmonary embolism 
(126). Moreover, FXII deficiency or inhibition of its activity protected the mice from 
ischemic brain injury in the transient middle cerebral artery occlusion model. The volume 
of infarcted brain in FXII deficient and FXII inhibitor-treated mice has been shown to be 
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reduced in comparison to wild-type animals. Targeting FXII reduced fibrin formation in 
ischemic vessels, and reconstitution of FXII deficient mice with human FXII restored 
fibrin deposition (127). Studies using intravital fluorescence microscopy revealed a 
severe defect in formation and stabilization of platelet rich occlusive thrombi induced by 
different means of injuries in FXII-/- mice (126,128). 
In a mouse model of arterial thrombosis, pretreatment with RNase prior to ferric 
chloride administration to the adventitial vessel surface, delayed occlusive thrombus 
formation and was associated with the reduced thrombus material (68). These results 
indicated that RNase can exert a strong antithrombotic effect in vivo and should be 
considered as a new therapeutical agent. 
 
1.1.3.3. Factor XII in fibrinolysis 
 
KLK and FXIIa cleave plasminogen directly, but much slower than t-PA or u-PA 
(129,130). FXII participates in fibrinolysis by enhancing the activation of PK on the 
endothelial cells surface. Activation of PK initiates two pathways of fibrinolysis. Firstly, 
KLK cleaves HMWK, liberating BK which is a potent stimulator of t-PA release from 
endothelial cells (131,132). Secondly, KLK converts prourokinase into two-chain u-PA 
(133). Increased incidence of venous thrombosis (134-136), myocardial infarction (137-
140) and re-thrombosis of coronary arteries after thrombolytic therapy in FXII deficient 
patients has been reported by some investigators (141,142). Further studies are required 
to determine whether FXII deficiency is associated with decreased fibrinolysis.  
 
1.1.3.4. Mitogenic activities of FXII 
 
FXII has been reported to be a potent mitogen for human hepatoma (Hep2) cells 
(91), smooth muscle cells, ATII cells and endothelial cells. FXII is able to stimulate cell 
proliferation in concentration ten times lower than its plasma concentration. CTI, a 
specific FXII protease inhibitor, has been shown to block FXII mitogenic activities. FXII-
induced mitogenesis may be mediated via activation of the mitogen-activated protein 
kinase (MAPK)/ERK pathway (90), since exposure of A10 cells (primary rat aortic 
smooth muscle cells) to FXII resulted in ERK1/2 phosphorylation. 
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1.1.4. Characterization of FXII promoter 
 
Thus far there is not much data on the regulation of FXII expression in the liver and 
other organs. FXII production in the liver is known to be regulated by estrogens. Previous 
reports demonstrated the induction of FXII gene transcription by 17β-estradiol in 
transiently transfected mouse NIH3T3 fibroblasts and human HepG2 cells. Furthermore, 
it was shown that a 230-bp fragment of FXII promoter, spanning nucleotides -181/49, 
conferred estrogen mediated transcription changes, suggesting that a functional estrogen 
responsive element (ERE) resides in this region. The lower response to estrogen was 
observed when longer fragments of FXII promoter were used, indicating the presence of a 
silencer located further upstream. The presence of ERE in the FXII promoter could 
explain estrogen-induced increase of FXII concentration in plasma (143-145). Four 
putative binding sites for the hepatocyte nuclear factor-3 (HNF-3) were recognized in the 
5'-flanking region of the FXII gene (146,147). 
Another study identified IL-6, a regulator of acute phase response, as a 
downregulator of FXII expression in HepG2 cells. Neither IL1-β nor TNFα changed FXII 
expression in HepG2 cells (148).  
It has been reported that FXII mRNA can be detected not only in the liver, but also 
in the lung, brain, placenta (149) and porcine endometrium (150), but the role of FXII in 
these organs and the regulators of its synthesis have never been studied. 
 
1.2. Idiopathic pulmonary fibrosis 
 
IPF is defined as a distinct type of chronic fibrosing interstitial pneumonia of 
unknown cause limited to the lungs and associated with a histological pattern of usual 
interstitial pneumonia. IPF lungs are characterized by architectural destruction, dense 
scarring with honeycombing and scattered fibroblasts foci (areas of intensive fibroblast 
proliferation) (151). IPF has a progressive and usually fatal course with an average 
survival rate of 2–3 years following diagnosis (152,153). Patients with IPF are usually 
between 50 to 70 years old and the incidence is 7.4 cases per 100 000 for women and 
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10.7 cases per 100 000 for men per year. The incidence, prevalence and death increases 
with age (154).  
To date, most treatment strategies have been based on eliminating or suppressing 
the inflammatory component. No pharmacological therapy has been proven to be 
effective in IPF treatment. All currently available therapeutic trials in IPF are severely 
limited by the lack of clear understanding of the disease etiology (151). The original 
hypothesis of the pathogenesis of IPF is that chronic inflammation in response to 
unknown etiological agents (idiopathic) leads to tissue destruction, initiation and 
propagation of wound healing responses and, subsequently, to progressive fibrosis. A 
recent proposal indicates that inflammation is necessary to trigger the initiation of the 
fibrotic process, but plays a minor role in the progression of the disease. In contrast to 
other forms of chronic interstitial lung diseases such as sarcoidosis and hypersensitivity 
pneumonitis, IPF is characterized by only limited inflammation. Recently, it has been 
suggested that IPF is mainly a disorder of alveolar epithelial injury, abnormal alveolar 
wound repair and remodelling (155,156). 
 
1.2.1. Role of Transforming Growth Factor- in the pathogenesis of 
lung fibrosis 
 
TGF-1 is a highly pleiotropic cytokine which plays a fundamental role in wound 
healing, embryonic development and disease states associated with inflammation and 
proliferation, for example tissue fibrosis. In the adult mice, TGF- overexpression in the 
lungs leads to progressive pulmonary fibrosis (157). TGF- is thought to promote fibrotic 
responses in the lungs mainly due to supression of alveolar epithelial cell proliferation, 
stimulation of fibroblast proliferation, activation of resident lung cells including epithelial 
cells, which differentiate into collagen-producing myofibroblasts. TGF-1 enhances 
synthesis and inhibits degradation of extracellular matrix components (158,159). 
Moreover, recent studies suggest that TGF-1 may contribute to fibrotic conditions by 
modulating procoagulant and fibrinolytic activities. In particular, TGF-1 has been 
shown to upregulate the expression of TF (160), the key initiator of the extrinsic 
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coagulation pathway, and of PAI-1 in different cell populations including fibroblasts 
(161,162).  
The cellular response to TGF-1 involves ligand binding to TGF- receptor type II 
(TII) which phosphorylates TGF- receptor type I (TRI). Activated TRI 
phosphorylates receptor associated Smads (Smad 1, 2, 3, 5, and 8), promoting their 
heterodimerization with common-mediator Smad (Smad 4) and their translocation from 
the cytoplasm to the nucleus. Within the nucleus, the Smad heterocomplex interacts with 
canonical smad-binding elements (SBEs) of target genes to activate their transcription 
(163,164). Human Smad 3 and Smad 4 have been shown to bind to SBE comprising 
CAGA box (161). 
 
1.2.2. Bleomycin model of lung fibrosis 
 
Different models of pulmonary fibrosis have been developed over the years, 
including radiation damage, instillation of bleomycin, silica or asbestos, gene transfer 
employing fibrogenic cytokines and transgenic mice (165). None of them mimic all 
features of human IPF. However, the standard agent for induction of experimental 
pulmonary fibrosis in animals is bleomycin. Bleomycin is a chemotherapeutic antibiotic, 
produced by the bacterium Streptomyces verticillus (166). It has been used as a drug in 
human cancer treatment.  
Bleomycin induces the production of superoxide and hydroxide free radicals. Free 
radicals cause single and double-strand DNA breaks in tumor cells and thereby interrupt 
the cell cycle (167). Its use in animal models of pulmonary fibrosis is based on bleomycin 
pulmonary side-effects. Bleomycin causes lung fibrosis in 10% of patients treated with 
this drug. An overproduction of reactive oxygen species leads to epithelial cell injury, 
inflammatory response, activation of fibroblasts and as a consequence to fibrosis (168). 
The lungs poorly express bleomycin hydrolase, a bleomycin-inactivating enzyme, and 
therefore are more susceptible to bleomycin-induced tissue injury (169). Bleomycin as an 
inducer of experimental lung fibrosis was first described in dogs (170), later in mice 
(171). After intratracheal instillation bleomycin causes inflammatory and fibrotic 
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reactions within a short period of time. The switch between initial elevation of pro-
inflammatory cytokines and fibrosis appears to occur around day 9 post application (168). 
Despite mimicking typical histological hallmarks of the human disease, the 
bleomycin model also has many limitations. Firstly, bleomycin triggers an acute lung 
injury and inflammatory response, while inflammation in IPF is limited. Secondly, 
bleomycin-induced fibrosis is at least partially reversible (172), in contrast to irreversible 
progression of IPF (173). 
 
1.2.3. Role of coagulation in the pathogenesis of idiopathic 
pulmonary fibrosis 
 
Alterations of the alveolar haemostatic balance and excessive deposition of 
intraalveolar fibrin have been observed in the lungs of IPF patients. Intraalveolar fibrin 
accumulation, observed under these conditions, arises from the imbalance between 
locally produced pro- and anti-coagulant factors, in combination with the leakage of 
plasma proteins (including fibrinogen) into the alveolar space. Increased procoagulant 
activity in BAL fluids of patients with IPF is accompanied by a decreased fibrinolytic 
activity (174,175). Identical alterations of the haemostatic balance in the alveolar space 
have been observed in the bleomycin animal model of pulmonary fibrosis (176). In 
clinical and experimental lung fibrosis the procoagulant response is mainly attributable to 
TF associated with FVIIa, whereas the decreased fibrinolytic activity is ascribed to the 
inhibition of u-PA and t-PA by PAI-1 as well as the blockage of plasmin by α2-plasmin 
inhibitor (174-176). Although fibrin is required for reparative processes and normal 
wound healing, persistent and excessive deposition of extravascular fibrin is thought to 
contribute to the pathomechanisms of fibrotic lung diseases in several ways. Fibrin may 
serve as a reservoir of profibrotic growth factors (177). It incorporates and inactivates 
pulmonary surfactant, the lung lipoprotein complex critical for maintaining low alveolar 
surface tension (178,179). Surfactant dysfunction leads to atelectasis and loss of lung 
compliance. Moreover, inactivation of the surfactant system, in conjunction with 
“glueing” of the adjacent alveolar walls by fibrin, is thought to provide a provisional 
matrix on which fibroblasts proliferate and produce collagen (180). 
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In addition, the u-PA/PAI-1 system may contribute to the development of lung 
fibrosis by regulating of cell migration, cell adhesion and cell proliferation (181,182). 
Furthermore, various coagulation proteases such as thrombin, FXa and the TF-FVIIa 
complex exhibit cellular activities that may also contribute to fibrotic processes in the 
lung. Most of these functions are mediated via proteolytic activation of protease activated 
receptors (PARs). For instance, thrombin and FXa stimulate fibroblast proliferation and 
procollagen production in a PAR-1-dependent manner (183,184). Additionally, thrombin 
induces differentiation of normal lung fibroblasts to myofibroblasts via PAR-1 activation 
(185). Furthermore, activation of PAR-1 by thrombin, FXa and by the TF-FVIIa complex 
can increase the expression of profibrotic and proinflammatory cytokines (186,187). A 
potential role of PAR-1 in pulmonary fibrosis is underscored by the recent finding which 
demonstrated that PAR-1 deficient mice are protected against bleomycin-induced lung 
fibrosis (188). Additional evidence underlying the importance of cellular effects mediated 
by haemostatic factors in the development of lung fibrosis came from the recent 
observation which indicated no protection against bleomycin-induced lung fibrosis in 
fibrinogen-null mice (189). Despite a well described role of the extrinsic coagulation 
pathway in the pathogenesis of IPF, the impact of intrinsic coagulation factors on the 
development of this disease is not known. 
 
Aim of the study 
________________________________________________________________________ 
2. Aim of the study 
 
It is well known that dysregulation of alveolar haemostatic balance contributes to 
the development of chronic fibrotic interstitial lung diseases, such as IPF. Activation of 
the extrinsic coagulation pathway and inhibition of fibrinolysis are recognized as major 
factors responsible for the procoagulant state observed in IPF. The involvement of the 
extrinsic coagulation pathway in the pathogenesis of IPF is well known, however the role 
of the intrinsic coagulation pathway in this process has not been reported. The present 
study was undertaken to elucidate the contribution of FXII, the key contact phase 
protease, in development of lung fibrosis. 
In this context, the research focus was: 
1. to ascertain the expression pattern of FXII, FXI and HMWK in the lungs of IPF 
patients and bleomycin challenged mice 
2. to investigate whether knockout or inhibition of FXIIa has a therapeutic effect on 
the development of bleomycin-induced lung fibrosis 
3. to evaluate whether BK mediates FXII profibrotic activities 
4. to elucidate the signaling pathways in the FXII-mediated proliferation of lung 
fibroblasts 
5. to describe the molecular mechanism underlying FXII expression in lung 
fibroblasts. 
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3. Materials and methods 
3.1. Materials 
3.1.1. Equipment 
 
Name  Company 
Bacteria culture incubator Heraeus, Germany 
Cell culture incubator Heraeus, Germany 
Electrophoresis chambers Biometra, Germany 
Falcon tubes Greiner Bio-One, Germany 
Film cassette Kodak, USA 
Filter tips: 10; 100; 1000 μl Eppendorf, Germany 
Fluorescence and light microscope Leica, Germany 
Gel blotting paper Amersham Biosciences, UK 
Multifuge centrifuge Heraeus, Germany 
PCR-thermocycler Biometria, Germany 
Petri dishes Greiner Bio-One, Germany 
Pipetboy Eppendorf, Germany 
Pipets Eppendorf, Germany 
Power supply Biometria, Germany 
Radiographic film Amersham Biosciences, UK 
Sequence Detection System 7700  Applied Biosystems, USA 
Tissue culture chamber slides BD Falcon, USA 
Tissue culture dishes Greiner Bio-One, Germany 
Transilluminator BioDocAnalyzer Biometria, Germany 
Ultra Microplate Reader EL 808 Bio-Tek Instruments, Germany 
Water bath for cell culture Medingen, Germany 
Western blot chambers  Biometra, Germany 
Vortex machine VWR, Germany 
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3.1.2. Reagents 
 
Product Name Company 
Ammonium persulfate Sigma-Aldrich, Germany 
Aprotinin Sigma-Aldrich, Germany 
1-butanol (n-butyl alcohol) Merck, Germany 
2-mercapto-ethanol Sigma-Aldrich, Germany 
2-propanol Fluka, Germany 
Acetic acid Sigma-Aldrich, Germany 
Acetone Roth, Germany 
Acrylamide solution, Rotiphorese gel 30 Roth, Germany 
Agarose Fluka, Germany 
Albumine, bovine serum Sigma-Aldrich, Germany 
Ammonium acetate Sigma-Aldrich, Germany 
Ammonium formate Sigma-Aldrich, Germany 
Brillant blue G Sigma-Aldrich, Germany 
Calcium chloride Sigma-Aldrich, Germany 
DMEM  Gibco BRL, Germany 
Dimethyl sulfoxide Roth, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Germany 
DNA ladder (100bp, 1kb) Fermantas, Germany 
Ethanol absolut Roth, Germany 
Ethidium bromide Sigma-Aldrich, Germany 
Ethylene glycol-bis(ß-amino-ethylether)-
N,N,N',N'tetraacetic acid (EGTA) Sigma-Aldrich, Germany 
Ethylenediamine-tetraacetic acid (EDTA) Sigma-Aldrich, Germany 
ECL plus Western blotting detection system  Amersham Biosciences 
Fetal calf serum (FCS) HyClone, USA 
Formaldehyde Sigma-Aldrich, Germany 
Glycerol Roth, Germany 
Glycine Roth, Germany 
Haemalaun Roth, Germany 
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High fidelity DNA polymerase Fermantas, Germany 
2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate 
(HEPES) Roth, Germany 
Hydrochloric acid  Roth, Germany 
Leupeptin Sigma-Aldrich, Germany 
Magnesium chloride Sigma-Aldrich, Germany 
Methanol Roth, Germany 
Milk powder Roth, Germany 
MuLV reverse transcriptase   Applied Biosystems, USA 
N,N’-methylene-bis-acrylamide Sigma-Aldrich, Germany 
Penicillin/streptomycin Invitrogen, Germany 
PCR nucleotide mix Fermantas, Germany 
Potassium chloride Roth, Germany 
Potassium phosphate monobasic Sigma-Aldrich, Germany 
Random hexamers Applied Biosystems, USA 
RNAse inhibitor Applied Biosystems, USA 
SDS  Sigma-Aldrich, Germany 
Sodium chloride Sigma-Aldrich, Germany 
Sodium citrate tribasic dihydrate Sigma-Aldrich, Germany 
Sodium deoxycholate Sigma-Aldrich, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Germany 
Sodium hydroxide Sigma-Aldrich, Germany 
Sodium phosphate (monobasic, anhydrous) Sigma-Aldrich, Germany 
Sodium vanadate Sigma-Aldrich, Germany 
TEMED Sigma-Aldrich, Germany 
Tris Roth, Germany 
Triton X-100 Sigma-Aldrich, Germany 
Trypsin/EDTA PAA Laboratories, Austria 
Tween 20 Sigma-Aldrich, Germany 
 
Materials and methods 
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3.2. Methods 
 
3.2.1. Intratracheal bleomycin administration 
 
Male mice (C57BL/6 strain) weighing between 20-22 g were used in all 
experiments. Mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). 
The animals were kept according to NIH guidelines and the experiments were undertaken 
with the permission of the local authorities. The animals were anesthetized by 
intraperitoneal injection of a mixture of ketamine hydrochloride and xylazine 
hydrochloride. Bleomycin (Almirall Prodesfarma, Barcelona, Spain) in a dosis of 5U/kg 
body weight was given by aerosol. For bleomycin delivery, the animals were 
orotracheally intubated and mechanically ventilated. A microsprayer (Penn-Century Inc, 
Philadelphia, PA) was filled with 100 µl of saline solution containing bleomycin, 
introduced into the tracheal cannula, positioned slightly above the carina and aerosol 
generation was achieved under end-expiratory breath arrest by rapidly emptying the 
syringe. Control mice received vehicle only (0.9% saline). Five mg/kg body weight of 
CTI (Calbiochem, Darmstadt, Germany) and 8 mg/kg body weight of PCK (Bachem, 
Weil am Rhein, Germany) both diluted in 0.9% saline, were administered intratracheally 
on day 9, 12, 15 and 18. The mice were sacrificed after 21 days post application (if not 
otherwise indicated) with a lethal dose of ketamine and xylazine. FXII deficient mice 
were kindly provided by Dr. T. Renne (Karolinska Institutet, Stockholm, Sweden). 
Bradykinin receptor 1/2 knockout mice were kindly provided by Prof. M. Bader (Max-
Delbrück-Center for Molecular Medicine, Berlin, Germany). 
.   
 
3.2.2. Pulmonary compliance measurements 
 
The mice were tracheotomised and ventilated in a volume driven mode at a positive 
end-expiratory pressure of 0 kPa. Respiration rate was set at 20 breaths/min and 
ventilation pressure was recorded while inflating the lung at a tidal volume of 200 µl.   
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3.2.3. Lung preparation 
 
After sacrificing the animals, the chest was opened and the lungs were flushed via a 
catheter that was placed into the pulmonary artery with phosphate-buffered saline (PBS; 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). Once the 
effluent was clear of blood, the lungs were removed and placed in paraformaldehyde or 
nitrogen for further examination. For cell isolation the lungs were placed in a PBS buffer. 
 
3.2.4. Isolation of murine and human lung fibroblasts and cell culture 
 
Lung tissue specimens were obtained from IPF patients who underwent lung 
transplantation at the Department of Cardiothoracic Surgery of the Medical University of 
Vienna, Austria, director W. Klepetko. Non-utilized donor lungs or parts of donor lungs 
that were not implanted due to lack of compatibility (for instance oversized grafts) served 
as a control. All investigations were approved by the local ethics committee and written 
informed consent was obtained from all participants or their next-of-kin. 
Human lung specimens of the pulmonary parenchyma and mouse lungs were 
chopped into < 1 mm3 pieces. The minced pieces were washed twice with PBS and then 
plated in 100-mm dishes (Greiner-bio-one, Frickenhausen, Germany). The specimens 
were cultured with Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Karlsruhe, 
Germany) supplemented with 10 % fetal calf serum (FCS; HyClone, South Logan, UT), 
and 1 % penicillin/streptomycin (Invitrogen) in a humidified atmosphere of 5 % CO2 at 
37 C. The purity of isolated fibroblasts was verified by positive staining for vimentin, 
fibronectin and collagen IV. All experiments were carried out with lung fibroblasts from 
passages 3-4. The mouse NIH3T3 fibroblasts were cultured in DMEM supplemented 
with 10 % FCS, and 1 % penicillin/streptomycin in a humidified atmosphere of 5 % CO2 
at 37 C. 
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3.2.5. Microdissection of lung tissue and alveolar epithelial type II cells  
 
Frozen specimens of lungs were sectioned at 10 µm in cryostat, mounted on 
noncoated, thin glass slides and stained with haemalaun (Roth, Karlsruhe, Germany) for 
45 seconds. The sections were then immersed in 70% and 96% ethanol until use. Not 
more than 10 sections were prepared at once to restrict the storage time. Chosen areas of 
lung specimen were laser-microdissected under visual control (PALM, Bernried, 
Germany). Tissue was harvested by a syringe needle and transferred into a reaction tube 
containing 10 µl fist strand buffer (FSB, 52 mM Tris pH 8.3, 78 mM KCl, 3.1 mM 
MgCl2,). Samples were frozen in liquid nitrogen and stored for further preparation.  
For ATII cell microdissection, cryostat sections (10 µm thick) were mounted on 
poly-L-lysine (0.01%, Sigma, Deisenhofen, Germany)-covered slides and stored in 
acetone for 5 minutes. For surfactant protein C precursor (proSP-C) staining a polyclonal 
rabbit anti pro-SP-C antibody was applied (1:100 in PBS; Chemicon, Temecula, CA) 
followed by incubation with FITC-labeled goat anti-rabbit IgG (1:40 in PBS, Santa Cruz 
Biotechnology, CA). Not more than two sections were prepared at once to restrict the 
storage time. ATII cells were selected according to their staining pattern and lasser-
microdissected under visual control. Samples with 50 cell profiles each were snap frozen 
in liquid nitrogen and stored for further preparation.  
 
3.2.6. RNA isolation and reverse transcriptase reaction 
 
Total RNA was extracted using a PeqGOLD Total RNA Kit (PeqLab, Erlangen, 
Germany) according to the manufacturer’s instruction. One µg of RNA obtained from 
lung homogenate, microdissected lung specimens, isolated fibroblasts or microdissected 
ATII cells was used in a reaction containing 4 µl 5x FSB, 2 µl dNTP (10 mM each, 
Fermentas, St. Leon-Rot, Germany), 1 µl random hexamers (50 µM), 1 µl DTT (0.1 M), 
1 µl RNase inhibitor (40 U/µl) and 1 µl MuLV reverse transcriptase (200 U/µl, all from 
Applied Biosystems, Foster City, CA) in RNase-free water (final volume 20 µl). The 
reaction was incubated at 43ºC for 1 h and then at 94ºC for 2 min (TGradient 
Thermocycler, Biometra, Goettingen, Germany). 
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3.2.7. Real Time PCR  
 
Real time PCR was performed by a Sequence Detection System 7700 (Applied 
Biosystems). Reactions were set up with Platinum SYBR Green qPCR Super Mix-UDG 
(Invitrogen) using 2 l of cDNA. The -actin gene was used as a reference gene. Cycling 
conditions were 95°C for 6 min, followed by 45 cycles of 95°C for 20 s, 55°C for 30 s, 
and 73°C for 30 s. Melting curve analysis and gel electrophoresis were performed to 
confirm the exclusive amplification of the expected PCR product. Gene expression was 
assessed using the 2-∆∆CT method as already described (190). The fold change in target 
gene relative to the endogenous control β-actin was determined by using the equation fold 
change=2-∆∆CT, where -∆∆CT=(CtTarget – CtActin)treated – (CtTarget – CtActin)control. Primer 
sequences are listed in Table 1. 
 
Table 1. Primer sequences. 
GENE PRIMER SEQUENCES  
human FXII F:5'-ACG ACC TGG CTC TGT TGC-3'  
R:5'-CTT GGC AGG CAC ACC GG-3'  
human FXI F:5'-TCT GGC TTG TAT TAG GGA C-3'  
R:5'-TCT TTG GGC CAT TCC TGG-3'  
human HMWK F:5'-AAG AGT ACA GGT GGT CGC-3' 
R:5'-CAA TCT AGG CTT TGG CCA AG-3'  
human β-actin F:5'-ATT GCC GAC AGG ATG CAG GAA-3' 
R:5'-GCT GAT CCA CAT CTG CTG GAA-3'  
murine FXII F:5'-ACA GTG CTC TGC GAG GTG G-3' 
R:5'-CGT TAG AGT TGG AGC AGC GAT-3'  
murine FXI F:5'-TTA CAC AGA TTT TCA GCG GCC-3' 
R:5'-TGT GTA CCC CCA TCC AGT CAC-3'  
murine HMWK F:5'-GGA GAA CAA AGT CGT CCC GA-3' 
R:5'-TGT GAC ACT CCG GAA AGG AGA-3'  
murine β-actin F:5'-AGA GGG AAA TCG TGC GTG AC-3'  
R:5'-CAA TAG TGA TGA CCT GGC CGT-3'  
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3.2.8. Protein isolation and quantification 
 
Harvested cells and frozen lungs specimens were lysed in RIPA buffer (50 mM Tris-HCL 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 1% Sodium deoxycholate, 0.1% 
SDS), which contained a protease inhibitor cocktail (Roche, Mannheim, Germany). 
Lysates were incubated on ice for 30 min and then centrifuged (10000 rpm for 10 min at 
4ºC). Supernatants were placed in new tubes and stored in -80˚C. Protein quantification 
was performed using BCATM Protein Assay Kit (Pierce, Rockford, IL) according to the 
manufacturer’s instructions. Different bovine serum albumin (BSA) concentrations were 
used as a standard.  
 
3.2.9. SDS polyacrylamide gel electrophoresis 
 
Protein samples were mixed with 5x SDS-loading buffer (0.25 mol/l Tris-HCl pH 6.8, 
10% (w/v) SDS, 50% glycerol, 10% β-mercaptoethanol), boiled for 10 min, loaded onto 
the SDS polyacrylamide gel (stacking gel: 4% acrylamide:bisacrylamide, 125 mM Tris-
HCl pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% (v/v) TEMED; resolving gel (10%): 
10% acrylamide:bisacrylamide, 375 mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) 
APS, 0.1% (v/v) TEMED) and run in a SDS-running buffer (25 mM Tris, 250 mM 
Glycine, 0.1% (w/v) SDS) at 100V.  
 
3.2.10. Immunoblotting 
 
Proteins separated on SDS polyacrylamide gel were transferred to a PVDF membrane 
(Amersham Biosciences, Freiburg, Germany) using the wet transfer technique in a 
transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol) for 1 h at 100V. After 
blocking with 5 % non-fat dry milk in tris-buffered saline (TBS; 25 mM Tris-HCl, 150 
mM NaCl, pH 7.5) containing 0.1 % (v/v) Tween 20 (TBS-T), the membranes were 
incubated at 4C overnight with one of the following antibodies: goat anti-FXII (Zytomed 
Systems, Berlin, Germany), goat anti FXI (Abcam, Cambridge, UK), rabbit anti-HMWK 
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(Abcam), mouse anti-phospho-p44/42, rabbit anti-phospho-Akt, rabbit anti-phospho-p38, 
rabbit anti-phospho-Smad 3, rabbit anti-phospho-c-jun (all from Cell Signaling, Frankfurt 
am Main, Germany), rabbit anti-phospho-JNK (R&D Systems, Wiesbaden, Germany), 
mouse anti-cyclin D1 (Cell Signaling), goat anti-uPAR (Santa Cruz Biotechnology), 
rabbit anti-lamin B or rabbit anti-tubulin (both from Abcam). All primary antibodies were 
diluted 1:1000 in 1% BSA in TBS-T. After a 1 h incubation with peroxidase-labelled 
secondary antibody (1:3000 in 5% non-fat dry milk in TBS-T, all from Dako, Gostrup, 
Denmark) proteins were detected using ECL Plus Kit (Amersham Biosciences). To 
determine the amounts of protein loaded on the gel, blots were incubated for 1 hour in a 
stripping buffer (100 mM glycine, 1% HCl) and reprobed using an anti-β-actin antibody 
(Sigma-Aldrich) or one of the following anti-pan antibodies: anti-p44/42, rabbit anti-Akt, 
rabbit anti-p38, rabbit anti-Smad 3, rabbit anti-c-jun (all from Cell Signaling), rabbit anti-
JNK (R&D Systems). 
 
3.2.11. Immunocytochemistry 
 
For immunocytochemical analysis, HLF were fixed with 4 % paraformaldehyde for 
10 min, permeabilized with 0.2 % Triton X-100 in PBS for 10 min, blocked with 3 % 
BSA in PBS for 1 h at room temperature, and incubated overnight at 4 C with one of the 
following antibodies: mouse anti-FXII, rabbit-anti-collagen IV, mouse anti-fibronectin 
(all from Abcam), goat anti-vimentin (Santa Cruz Biotechnology), and rabbit anti-
phospho-Smad 3 (Cell Signaling). All primary antibodies were diluted 1:100 in PBS. 
Slides were incubated with a rhodamine-conjugated secondary antibody (Dianova, 
Hamburg, Germany), and mounted with Vectashield mounting medium (Vector, 
Burlingame, CA). Nuclei were visualized by 4, 6-diamidino-2-phenylindole (DAPI) 
staining. Controls were performed by substituting the primary antibody by a non-specific 
antibody. Images were captured by a Leica DMR microscope (Leica, Heidelberg, 
Germany) with 40/1.25-0.75 oil-objective at room temperature and photographed using 
MetaMorph 7.0 (Molecular Devices, Downingtown, PA). All images illustrated are 
representative of at least four other areas per section, seen on at least three independent 
sections. 
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3.2.12. Immunohistochemistry 
 
Paraffin-embedded, formalin-fixed lung tissue was sectioned at 5 microns and 
processed for immunohistochemical staining using one of the following antibodies: rabbit 
anti-FXII (1:100 in PBS, kindly provided by Dr. T. Renne), goat anti-FXI (1:500 in PBS, 
Abcam), rabbit anti-HMWK (1:400 in PBS, Abcam), rabbit anti-fibrinogen (1:800 in 
PBS, Dako, Gostrup, Denmark) and ZytoChem Plus AP-Fast Red Kit according to the 
manufacturer’s instructions (Zytomed Systems). Negative controls were obtained in all 
cases by omitting the primary antibody. The specificity of the staining was not proved by 
preabsorption of the primary antibody with the corresponding antigen.  
 
3.2.13. Proliferation assay  
 
The primary murine lung fibroblasts were seeded in 48-well plates, starved in 
serum free DMEM for 24 h, and then stimulated with various concentration of FXIIa 
(American Diagnostica, Stamford, CT). In some experiments cells were preincubated 
with anti-uPAR (5 µg/ml, R&D Systems), anti-β1-integrin or anti-α5-integrin (1:200 in 
DMEM, both from Millipore, Schwalbach, Germany) blocking antibodies 1-2 h before 
exposure to FXIIa. In addition, in some experiments 10.0 μM PD98059, 5 μM SP600125, 
0.7 μM Wortmannin, 3 μM SB203580 (all from Calbiochem) were added to the cell 
culture medium 1-2 h prior to the addition of FXIIa. Cells were treated with 3-9 µg/ml 
FXIIa alone or in the presence of 12.6 μg/ml CTI (Calbiochem), or 7 μM uPAR synthetic 
peptides (kindly provided by Prof. A. Schmaier). After 24-36 h the cells were exposed to 
[3H]Thymidine (0.2 µCi per well, PerkinElmer, Waltham, MA) for 6-12 h, rinsed three 
times with PBS and solubilized with 0.2 ml 0.5 M sodium hydroxide; 0.1 ml of the 
solubilized material was quantified by liquid scintillation counting (TRI-CARB® 1500, A 
Canbera Company, Meriden, CT). [3H]Thymidine incorporation was expressed as 
absolute radioactivity (cpm, counts per minute per well). 
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3.2.14. Immunoprecipitation 
 
Primary murine fibroblasts were either unstimulated or stimulated with 6 µg/ml 
FXIIa for 30 min and lysed in a buffer containing 20 mM HEPES pH 7.5, 10 mM EGTA, 
40 mM β-glycerophosphate, 1% Triton X-100, 2.5 mM MgCl2, 1 mM DTT, 2 mM 
PMSF, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 2 mM sodium vanadate. After 30 min 
incubation at 37ºC, insoluble material was pelleted by centrifugation at 10 000 rpm for 10 
min at 4ºC. A hundred µl of cell lysate was further incubated overnight at 4ºC with the 
chicken anti-uPAR antibody (dilution 1:20, kindly provided by Dr. V. Magdolen) or with 
5 µg of a nonspecific antibody. Next, 100 µl of G-Sepharose (Amersham Biosciences) 
was added and immune complexes were allowed to bind for 1 h at 4ºC. Next, the beads 
were washed four times with a lysis buffer, and adsorbed material was eluted in a 2x SDS 
loading buffer. After boiling, the uPAR bound proteins were analyzed by Western 
blotting using mouse anti-FXII antibody (1:1000 in 1% BSA in TBS-T, Abcam).  
 
3.2.15. Generation of FXII promoter constructs and site-directed 
mutagenesis  
 
The human FXII promoter fragments were amplified by PCR from human lung 
DNA using a Long PCR Enzyme Mix (Fermantas) according to the manufacturer’s 
instruction. Cycling conditions were: 95 °C for 5 min, followed by 35 cycles at 95 °C for 
30 s, 55 °C for 30 s, and 72 °C for 3 min. The following primers were used: human FXII-
1630 forward 5'-CCGCTCGAGTGCTCTGTGCTTAGTAACC-3'; human FXII-907 
forward 5'-CCGCTCGAGCAGCTACCCAGGAGGCT-3'; human FXII-577 forward 5'-
CCGCTCGAGGCGTGGTGGTGGGCTCCT-3'; human FXII-299 forward 5'-
CCGCTCGAGCTTAACCTCCTGATCTCC-3'; human FXII-183SBE-272 forward 5'-
CCGCTCGAGAAACTCCCAAACTTTCC-3'; human FXII reverse 5'-CCCAAGCTTC-
GTTGGTCCAGCTGCCTATC-3'. The PCR fragments were cloned into pGL3 Enhancer 
Vector (Promega, Mannheim, Germany) using XhoI and HindIII restriction sites (in 
bold). Point mutation was introduced into the CAGA box in pGL3-299 construct using 
the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to 
 28
Materials and methods 
________________________________________________________________________ 
the manufacturer’s instructions. The following primers were used: human FXII-299C/T 
forward 5’-CCACAGGACCTAGAGCATAAGAATG-3’, human FXII-299C/T reverse: 
5’-CATTCTTATGCTCTAGGTCCTGTGG-3’. Successful cloning and insertion of the 
mutation into the CAGA box were confirmed by sequencing. 
 
3.2.16. Transient transfection and luciferase assay 
 
NIH3T3 cells were transfected with indicated plasmids using FuGene6 (Roche) 
according to the manufacturer's instruction. After 48 h the cells were either unstimulated 
or stimulated with 10 ng/ml TGF-β1 (R&D Systems) for a further 24 h. Subsequently, the 
cells were harvested and assayed for luciferase reporter activity using a Promega 
Luciferase Assay Kit according to the manufacturer's instruction. Co-transfection with a 
pEGF-N1 (Clontech, Mountain View, CA) control vector was used to normalize for 
transfection efficiency.  
 
3.2.17. Antisense Oligonucleotides 
 
Pre-designed, commercially available siRNA sequences directed against human 
Smad 3 (Dharmacon, Chicago, IL), human JNK1 (Abnova, Heidelberg, Germany), and a 
universal negative-control siRNA (Ambion, Austin, TX) were employed. Cells were 
treated with siRNA (250 nM each) using the X-treme Gene siRNA Transfection Reagent 
(Roche). The siRNA-mediated downregulation of the target genes was assessed 72 h after 
transfection by Western blotting. At this time point the cells were either unstimulated or 
stimulated with 10 ng/ml TGF-ß1 for 24 h and the Western blots for FXII were prepared 
as described above.  
 
3.2.18. Chromatin immunoprecipitation 
 
Chromatin immunoprecipitation (ChIP) was performed using a Chromatin 
Immunoprecipitation Assay Kit from Millipore according to the manufacturer's 
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instruction. Briefly, NIH3T3 cells either unstimulated or stimulated with 10 ng/ml TGF-
β1 (R&D Systems) were treated with 1 % formaldehyde for 10 min. The cross-linked 
chromatin was then prepared and sonicated to an average size of 500-800 bp. The DNA 
fragments were immunoprecipitated with rabbit anti-Smad 3 antibody (1:200, Cell 
Signaling) or IgG isotype control (5 µg/ml, Sigma Aldrich) overnight at 4C. After 
reversal of cross-linking, the immunoprecipitated chromatin was amplified by PCR using 
the following primers: human FXII-299 bp forward: 5'- CTTAACCTCCTGATCTCC-3'; 
human FXII-299 bp reverse: 5'- CGTTGGTCC-AGCTGCCTATC-3'. PCR products were 
separated on the 2% agarose gel and visualized by ethidium bromide staining.  
 
3.2.19. Streptavidin pull-down assay 
 
The double-stranded biotinylated DNA fragment (SBE-283/-258: 5’-biotin–
CTTAACCTCCTGATCTCCACAGGACCCAGAGCATAAGAATGTCCC–3’ or SBE-
283/-258 C/T: 5’-biotin–CTTAACCTCCTGATCTCCACAGGACCTAGAGCATAAGAAT 
GTCCC–3’) spanning SBE was assayed for protein interaction in 100 l binding reaction 
containing 20 μg of nuclear extract, 20 pmol/µl of biotinylated template, and 1 μg of 
poly(dI-dC). After incubation for 1 h at 30 °C, streptavidin MagneSphere paramagnetic 
particles (Promega) pre-equilibrated in a binding buffer (20 mM HEPES pH 7.9, 80 mM 
KCl, 10 mM MgCl2, 10 % (v/v) glycerol, 2 mM DTT, 500 μg/ml of BSA and 0.05 % 
(v/v) Nonidet P-40) were added to the reaction, and incubated for another 1 h at 30°C. 
The DNA–protein complexes were washed three times with wash buffer (20 mM HEPES 
pH 7.9, 50 mM KCl, 6.25 mM MgCl2, 0.5 mM EDTA, 2 mM DTT, and 8.5 % (v/v) 
glycerol) using a magnetic device (Dynal MPC®-E, Magnetic Particle Concentrator). 
After boiling, the DNA-bound proteins were analyzed by Western blot using rabbit anti-
phospho Smad 3 antibody (1:1000 in 1% BSA in TBS-T, Cell Signaling). Nuclear 
extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagent 
(Pierce) according to the manufacturer’s instruction.  
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3.2.20. Statistics 
 
Data are presented as mean  SD unless otherwise stated. Normal distribution was 
analyzed by Shapiro-Wilk test. Statistical comparisons between two populations were 
performed using unpaired Student t-tests or Mann-Whitney test. Differences between 
multiple groups were compared by the One-way ANOVA analyse followed by the 
Tukey’s post test. A level of p<0.05 was considered statistically significant. The 
statistical significance between survival curves was assessed by the log-rank test. 
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4. Results 
 
4.1. Expression of FXII, FXI and HMWK is altered in 
idiopathic pulmonary fibrosis lungs  
 
To reveal the potential role of the intrinsic coagulation pathway in the pathogenesis 
of IPF, expression of FXII, FXI and HMWK in lung tissue from IPF patients and donors 
was analyzed using real-time PCR. As shown in Figure 4.1A, FXII and HMWK mRNA 
level were markedly upregulated in IPF lung specimens. The cell-specific expression of 
intrinsic coagulation pathway components was quantified in primary human ATII cells 
and fibroblasts derived from the lungs of IPF patients and donors. Lung fibroblasts 
isolated from IPF lung tissue expressed FXII mRNA at higher levels than those found in 
the cells from the donor lungs. FXII mRNA was not detected in ATII cells. FXI and 
HMWK expression in ATII cells and lung fibroblasts derived from the lungs of IPF 
patients was not changed when compared to the donor samples. Furthermore, expression 
of FXII, FXI and HMWK in alveolar septae microdissected from the fibrotic (F) and 
healthy (H) regions of IPF tissue was analyzed (Figure 4.1B). The mRNA level of FXII, 
FXI and HMWK in the healthy regions from IPF lungs was not changed in comparison to 
the levels found in the donor tissue (D) (Figure 4.1B). In contrast, there was significant 
upregulation of FXII, FXI and HMWK genes in the fibrotic areas of IPF lungs.  
In line with the mRNA expression, protein levels of FXII and HMWK were 
upregulated in IPF lungs (Figure 4.2A). An activity assay using FXII chromogenic 
substrate demonstated increased enzymatic activity of FXII in BAL fluid from IPF 
patients (Figure 4.2B). The specificity of the performed assay was proved by the 
blockade of FXII activity by its inhibitor, CTI. 
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Figure 4.1. mRNA level of FXII, FXI and HMWK is elevated in the lungs of IPF patients.  
(A) The expression of FXII, FXI and HMWK mRNA was assessed in donor (n=10) and IPF (n=10) lung 
tissue homogenates (LH) as well as in lung fibroblasts and ATII cells from donor (n=5) and IPF (n=5) 
lungs by real time PCR. Given is the fold-increase in mRNA expression in IPF specimens (normalized for 
-actin expression) versus values obtained for donor samples. (B) Expression of FXII, FXI and HMWK in 
the healthy (H) and fibrotic (F) regions of IPF lungs. Given is the fold-increase in mRNA expression in IPF 
specimens (normalized for -actin expression) versus values obtained for donor (D) samples; n=5 (C). 
Results are presented as mean ± SD, * p < 0.05; Student’s t-test. ND; not detected 
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Figure 4.2. Protein level of FXII, FXI and HMWK and FXII activity are elevated in the lungs of IPF 
patients. 
(A) FXII, FXI and HMWK expression in lung homogenates of donors and IPF patients as assessed by 
Western blotting. Representative donors (7 out of 20) and patients (7 out of 20) are shown. ß-actin served 
as a loading control. (B) FXII activity in BALF samples of donors (n=10) and IPF patients (n=10) in the 
absence or presence of FXII specific inhibitor CTI. Data are presented as box and whisker plots, in which 
the horizontal line within each box represents the median, the limits of each box represent the interquartile 
range and the whiskers represent the maximum and minimum values. Tested for statistical significance by 
Mann-Whitney test. Significance levels are indicated. 
 
Immunohistochemistry staining of FXII, FXI and HMWK was performed to 
characterize localization of these factors in donor and IPF lungs. As shown in Figure 4.3 
the expression of all intrinsic coagulation factors was markedly increased in IPF sections 
compared to donor tissue. The strongest immunoreactivity of FXII was observed in 
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fibroblasts and on the surface of ATII cells. FXI was mainly expressed in ATII cells and 
in fibroblasts, whereas HMWK was mostly present in monocytes. 
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Figure 4.3. Expression and localization of FXII, FXI and HMWK in lung tissue of donor and IPF 
patients.  
Immunohistochemical staining of FXII, FXI and HMWK in lung tissue sections obtained from donors and 
IPF patients. One representative IPF patient and one donor out of five per group are shown. Bar size is 
indicated.  
 
4.2. Expression of FXII, FXI and HMWK is elevated in 
bleomycin lungs 
 
To determine whether the findings in the IPF lungs translate to the animal model of 
lung fibrosis, the expression of FXII, FXI and HMWK was quantified in the lungs of 
bleomycin challenged mice. The real time PCR revealed upregulation of FXII, FXI and 
HMWK in lung homogenate from bleomycin-treated mice at day 4 and day 20 post 
bleomycin instillation (Figure 4.4). Interestingly, FXII mRNA was not detected in 
primary murine lung fibroblasts and ATII cells. FXI expression in ATII cells derived 
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from bleomycin lungs was not changed, while its expression in lung fibroblasts was 
upregulated at day 12 post bleomycin administration. There was significant upregulation 
of HMWK mRNA in lung fibroblasts at day 20 post bleomycin application, while no 
change in HMWK expression was observed in ATII cells. 
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Figure 4.4. mRNA level of FXII, FXI and HMWK is elevated in the lungs of bleomycin-treated mice. 
Real time PCR analysis of FXII, FXI and HMWK expression in control (saline; n=10) and bleomycin 
(n=10) lung homogenates as well as in lung fibroblasts and ATII cells isolated from the lungs of control 
(n=10) and bleomycin challenged (n=10) mice. Given is the fold-increase in mRNA expression in 
bleomycin-treated lungs (normalized for -actin expression) versus values obtained for control lungs. 
Results are presented as mean ± SD,*** p <0.0005, ** p <0.005,* p <0.05; Student’s t-test. 
 
 
As compared to findings from IPF tissue specimens, immunoblotting showed a 
similar upregulation of the FXII, FXI and HMWK protein level in lung homogenate at 
day 4 and 20 post bleomycin application (Figure 4.5).  
 35
Results 
________________________________________________________________________ 
 
 
Saline day 4 day 12 day 21 
55 FXII 
72 FXI 
72 
55 
43 
HMWK 
β-actin 40 
 kDa 
 
Figure 4.5. Increased protein level of FXII, FXI and HMWK in lung homogenates of control and 
bleomycin challenged mice.  
FXII, FXI and HMWK expression in lung homogenates of control (saline) and bleomycin-treated mice. 
Representative saline (3 out of 10) and bleomycin challenged mice at day 4 (3 out of 10), 12 (3 out of 10) 
and 21 (3 out of 10) post application are shown. ß-actin served as a loading control. 
 
 
Immunolocalization studies confirmed strong expression of FXII, FXI and HMWK 
in bleomycin-injured lungs (day 20 post application) compared to the weak signal 
observed in the lungs of saline treated mice (Figure 4.6). Weak FXII, FXI and HMWK 
staining in control lungs was mainly observed in alveolar macrophages. After bleomycin 
application strong FXII, FXI and HMWK immunoreactivity was visible in fibrotic 
regions and alveolar macrophages.  
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Figure 4.6. Expression and localization of FXII, FXI and HMWK in the lungs of control and 
bleomycin-treated mice.  
Representative histological section showing FXII, FXI and HMWK localization in the lungs from saline or 
bleomycin-treated mice. One representative bleomycin mouse and one control out of ten per group are 
shown. Bar size is indicated.  
 
 
4.3. FXII knockout or FXIIa inhibition protects against 
bleomycin-induced lung fibrosis 
 
To determine the role of FXII in lung fibrosis, mice deficient in FXII were 
challenged with bleomycin. As revealed by hematoxylin and eosin staining at day 21, 
wild type (WT) animals treated with bleomycin showed remarkable lung fibrosis 
characterized by a distortion of the normal lung architecture, increased interstitial wall 
thickness and an increased number of fibroblasts (Figure 4.7A). In contrast FXII deficient 
(FXII-/-) mice had decreased fibrotic changes in the lungs (Figure 4.7C). Trichrome 
staining was performed to assess abnormalities in lung collagen deposition after 
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bleomycin challenge. Accumulation of collagen was more remarkable in WT animals 
(Figure 4.7B) as compared to FXII-/- mice (Figure 4.7D). Finally, the mortality of FXII-/- 
mice was significantly lower in comparison to WT mice (Figure 4.7E). At day 21 post 
bleomycin challenge, the mortality of WT mice was 40%, whereas the mortality of FXII-/- 
was 5%.  
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Figure 4.7. FXII-/- mice are protected against bleomycin-induced lung fibrosis.  
Hematoxylin and eosin staining of lungs of (A) WT and (C) FXII-/- mice 21 days after bleomycin challenge. 
Trichrom staining of lungs of (B) WT and (D) FXII-/- mice 21 days after bleomycin administration. Green 
colour indicates collagen deposits. Representative lung tissue sections are demonstrated. Bar size is 
indicated. (E) Survival curve demonstrating mortality rate of WT and FXII-/- mice after bleomycin 
challenge, n=20 mice/group. Significant difference by log-rank test, p=0.007.  
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To determine whether fibrin deposition in the lungs of FXII-/- mice is impaired after 
bleomycin application, lung sections were stained with anti-fibrinogen antibody (Figure 
4.8). WT animals receiving bleomycin showed extensive fibrin deposition in fibrotic 
areas. Fibrin staining was observed in alveolar space in close proximity and in areas of 
fibrosis. A similar pattern was visible in the lungs of FXII-/- mice challenged with 
bleomycin.  
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Figure 4.8. Fibrin deposition in the lungs of FXII-/- mice is not impaired after bleomycin application. 
Fibrin immunostaining in lung tissue sections of bleomycin-treated WT and FXII-/- mice 21 days after 
bleomycin instillation. Red colour indicates fibrin. The photomicrographs were selected to illustrate the 
pattern and extent of fibrin deposition in the abnormal and normal regions of the lung for each experimental 
group. Representative lung tissue sections are demonstrated. Bar size is indicated.  
 
 
To evaluate the possible therapeutical effects of FXII inhibition on bleomycin-induced 
lung injury, the saline control mice and bleomycin challenged mice received CTI, a 
specific FXII activity inhibitor. Saline or CTI (at a dose 5 mg/kg body weight) were 
administered intratracheally at day 9, 12, 15 and 18. At day 21 the mice were sacrificed, 
the lung compliance was measured and lung tissue specimens were collected. Bleomycin-
treated mice which received saline showed severe fibrotic changes with loss of normal 
architecture and extensive collagen deposition (Figure 4.9C, D). Extensive fibrosis 
development was reflected by a strong decrease in compliance (Figure 4.9J). In contrast, 
histologic findings in the lungs of bleomycin-treated mice that obtained CTI 
demonstrated fewer fibrotic lesions (Figure 4.9G). Collagen accumulation as assessed by 
Trichrom staining was markedly reduced in FXII inhibitor-treated animals (Figure 4.9H). 
Moreover, the compliance of CTI-treated animals was significantly improved (Figure 
4.9J). At day 21 post bleomycin challenge, the mortality of saline-treated mice was 80 %,  
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Figure 4.9. FXIIa inhibitor (CTI) attenuates bleomycin-induced lung fibrosis.  
Hematoxylin and eosin staining of lung tissue sections at day 21 post (A,E) saline or (C,G) bleomycin 
application. Trichrom staining of lung tissue sections at day 21 post saline (B,F) or bleomycin (D,H) 
instillation. Green colour indicates collagen deposits. Representative lung tissue sections are demonstrated. 
Bar size is indicated. (I) Survival curve demonstrating mortality rate of saline- and CTI-treated mice after 
bleomycin challenge, n=5 mice/group. Significant difference by log-rank test, p=0.0416 (J) Lung 
compliance at day 21 after bleomycin or saline administration. Data are presented as box and whisker plots, 
in which the horizontal line within each box represents the median, the limits of each box represent the 
interquartile range and the whiskers represent the maximum and minimum values. n=5 mice/group; * p < 
0.05; Mann-Whitney test.  
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Figure 4.10. PCK administration does not improve bleomycin-induced lung fibrosis.  
Hematoxylin and eosin staining of lung tissue sections at day 21 post (A,E) saline or (C,G) bleomycin 
application. Trichrom staining of lung tissue sections at day 21 post saline (B,F) or bleomycin (D,H) 
instillation. Green colour indicates collagen deposits. Representative lung tissue sections are demonstrated. 
Bar size is indicated. (I) Survival curve demonstrating mortality rate of saline- and PCK-treated bleomycin 
mice, n=10 mice/group. Statistical comparison by log-rank test, p=0.28. (J) Lung compliance at day 21 
after bleomycin or saline administration. Data are presented as box and whisker plots, in which the 
horizontal line within each box represents the median, the limits of each box represent the interquartile 
range and the whiskers represent the maximum and minimum values. n=10 mice/group; ** p < 0.005; 
Mann-Whitney test. NS, not significant. 
 
whereas the mortality of animals, which received CTI was 20% (Figure 4.9I). The control 
animals, which received CTI, had no histological changes in the lung but they showed a 
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mild degree of inflammatory cell infiltration into airspaces (Figure 4.9E). This side effect 
of CTI may limit its therapeutical application. 
These findings led me to look for another FXII inhibitor which could be safely used 
in lung fibrosis treatment. PCK is the active-site directed inhibitor of activated FXII and 
KLK (93). Saline control mice or mice challenged with bleomycin received saline or 
PCK (at a dose of 8 mg/kg body weight) intratracheally at day 9, 12, 15 and 18. In 
contrast to previous results with CTI, after 21 days of bleomycin challenge, focal fibrotic 
lesions, destruction of lung architecture and collagen accumulation were seen in the lungs 
of both PCK- and saline-treated groups (Figure 4.10C, D, G, H) There was no significant 
difference in lung compliance between PCK-treated and untreated bleomycin animals 
(Figure 4.10J). After 21 days, when the experiment was terminated, seven of the 
untreated and four of the PCK-treated bleomycin mice died (Figure 4.10I). No 
histological changes in the control mice after PCK administration were observed (Figure 
4.10E). 
 
4.4. Bradykinin receptor 1/2 knockout mice are not protected 
against bleomycin-induced lung fibrosis 
 
FXIIa is a potent activator of plasma PK. Active KLK cleaves further HMWK to HKa 
and BK, which acts as a vasodilator and proinflammatory peptide through two G-protein-
coupled receptors: B1 and B2. To determine whether FXII-induced BK delivery 
contributes to the development of lung fibrosis, B1 and B2 receptors deficient mice 
(B1B2-/-) were challenged with bleomycin. After 21 days of bleomycin application, WT 
and B1B2-/- animals developed strong fibrotic changes and showed collagen accumulation 
in the lungs as evidenced by hematoxylin and eosin staining and Trichrom staining 
respectively (Figure 4.11A). No improvement in lung compliance (Figure 4.11C) and 
survival (Figure 4.11B) was observed in B1B2-/- in comparison to WT mice after 
bleomycin administration. 
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Figure 4.11. B1B2-/-  mice are not protected against bleomycin-induced lung fibrosis. 
(A) Hematoxylin and eosin (top) and Trichrom (bottom) staining of lung tissue sections of WT and B1B2-/- 
mice 21 days after bleomycin instillation. Green colour indicates collagen deposits. Representative lung 
tissue sections are demonstrated. Bar size is indicated. (B) Survival curve demonstrating mortality rate of 
WT and B1B2-/- mice after bleomycin challenge, n=20 mice/group. Statistical comparison by log-rank test, 
p=0.86. (C) Lung compliance at day 21 after bleomycin administration.  Data are presented as box and 
whisker plots, in which the horizontal line within each box represents the median, the limits of each box 
represent the interquartile range and the whiskers represent the maximum and minimum values. n=20 
mice/group; Mann-Whitney test. NS, not significant. 
 
 
4.5. FXII stimulates proliferation of lung fibroblasts  
 
FXII has been reported to act as mitogen for Hep2 cells, smooth muscle cells, ATII 
cells and endothelial cells (91). Taking into consideration that intensive fibroblast 
proliferation is a hallmark of lung fibrosis, it was of interest to check if FXII may control 
lung fibroblast proliferation as well. To answer this question murine lung fibroblasts were 
stimulated with an increasing concentration of FXIIa and [3H]-thymidine incorporation 
was measured. The dose-dependent increase in DNA synthesis was observed after FXIIa 
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treatment (Figure 4.12A). FXII-induced proliferation was blocked by FXIIa specific 
inhibitor, CTI. Additionally, increased cyclin D expression after exposure to FXIIa 
confirmed FXIIa mitogenic activities toward murine lung fibroblasts (Figure 4.12B). 
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Figure 4.12. FXIIa stimulates proliferation of murine lung fibroblasts. 
(A) [3H]-Thymidine incorporation in murine lung fibroblasts exposed to various concentration of FXIIa in 
the absence or presence of CTI (12.6 µg/ml). Data represent mean values ± SD from three independent 
experiments, each performed in triplicate; ** p < 0.005; * p < 0.05; ANOVA, Tukey’s post test. (B) Cyclin 
D1 expression in murine lung fibroblasts stimulated for 6 h with FXIIa (6 µg/ml) in the absence or presence 
of CTI (12.6 µg/ml). Data are representative of three independent experiments. ß-actin served as a loading 
control. 
 
In order to investigate the contribution of different signal transduction pathways to 
FXIIa-induced proliferation of murine lung fibroblasts, MAPKs and Akt phosphorylation 
kinetics in response to FXIIa stimulation were analyzed. A marked increase in p38, 
p44/42 and Akt activity was visible after 15 min, whereas no phosphorylation of JNK and 
c-jun was observed. CTI attenuated p44/42 and Akt phosphorylation after 30 min of 
FXIIa exposure. After determination of the phosphorylation kinetics, it was next analyzed 
whether interference with these pathways would affect FXIIa-induced proliferation of 
murine lung fibroblasts. To assess this question, specific inhibitors of PI3K, MEK and 
p38 kinases (Wortmannin, PD98059, and SB203580, respectively) were used and their 
effect on FXIIa mitogenic activities was evaluated. As shown in Fig. 4.13 B inhibition of 
MEK activity by PD98059 led to reduction of murine lung fibroblast proliferation in 
response to FXIIa. No change in DNA synthesis was visible when cells were pretreated 
with inhibitors of PI3K and p38 kinases.  
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Figure 4.13. p44/42 kinase regulates FXII-induced proliferation of murine lung fibroblasts. 
(A) Murine lung fibroblasts were treated for the indicated time points with FXIIa and the activity and 
expression of Akt, JNK, c-jun, p38 and p44/42 kinases were analyzed by Western blotting. 
Phosphoproteins were detected via phospho-specific antibodies as indicated. Equal loading was confirmed 
via pan-specific antibodies. Data are representative of three independent experiments. (B) [3H]-thymidine 
incorporation in murine lung fibroblasts pretreated with MEK, p38, and PI3K kinases specific inhibitors 
(PD98059, SB203580 and Wortmannin, respectively) 1 h prior to FXIIa (6 µg/ml) stimulation. Data 
represent mean values ± SD from three independent experiments, each performed in triplicate;* p < 0.05; 
ANOVA, Tukey’s post test. NS, not significant. 
  
FXII has been reported to bind to the endothelial cell surface in complex with 
gC1qR, uPAR and CK1. Furthermore, there are studies which indicate that uPAR is 
involved in FXII-induced endothelial cell proliferation (191). To investigate whether 
uPAR mediates FXIIa mitogenic activities towards murine lung fibroblasts, cells were 
treated with an anti-uPAR blocking antibody prior to FXIIa stimulation. Cell 
proliferation, as measured by [3H]-thymidine incorporation was blocked by an anti-uPAR 
antibody (Figure 4.14A). Moreover, experiments using peptides corresponding to uPAR’s 
domain 2 confirmed the importance of this receptor for FXIIa mitogenic activities and 
revealed the potential FXII binding site on uPAR. Peptide LRG20 (position 166-185) 
from uPAR’s domain 2 blocked an increase in DNA synthesis after FXIIa stimulation 
(Figure 4.14B). In comparison, peptide TCK from domain 2 (position 196-214) and 
random peptide had no effect on FXIIa-induced proliferation.  
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Figure 4.14. uPAR mediates FXIIa-induced murine lung fibroblast proliferation.  
(A) [3H]-thymidine incorporation in murine lung fibroblasts pretreated with an anti-uPAR blocking 
antibody (5 µg/ml) or IgG isotype control antibody (5 µg/ml) prior to FXIIa (6 µg/ml) stimulation. Data 
represent mean values ± SD from three independent experiments, each performed in triplicate; ** p < 
0.005; * p < 0.05; ANOVA, Tukey’s post test. (B) [3H]-thymidine incorporation in murine lung fibroblasts 
after exposure to FXIIa (6 µg/ml) in the presence or absence of peptides (7 µM) coresponding to domain 2 
of uPAR (LRG20 or TCK19) or random peptide (7 µM). Data represent mean values ± SD from three 
independent experiments, each performed in triplicate; * p < 0.05; ANOVA, Tukey’s post test.  
 
To confirm earlier findings, murine lung fibroblasts from uPAR deficient mice 
(uPAR-/-) were isolated and exposed to FXIIa. In contrast to WT cells, uPAR deficient 
lung fibroblasts did not respond to FXIIa (Figure 4.15A). These data indicate that uPAR 
is required for FXIIa mitogenic activities. This observation raised the question whether 
uPAR interacts with FXIIa protein. To investigate this issue, an immunoprecipitation 
assay was performed. For immunoprecipitation, lysates were prepared from cells either 
stimulated or unstimulated with FXIIa for 30 min. Using an anti-uPAR antibody FXIIa 
was immunoprecipitated from lysates of cells exposed to FXIIa (Figure 4.15B). uPAR 
did not immunoprecipitate with isotype control antibody.  
Taken together, these results demonstrated that FXIIa induced murine lung 
fibroblast proliferation in a uPAR dependent manner. Based on the fact that uPAR has no 
kinase activity and does not directly interact with intracellular pathways, the question 
whether other proteins are involved in this mechanism was raised. It is unclear how 
glycosylphosphatidylinositol-anchored uPAR, which lacks a transmembrane structure, 
mediates signal transduction. It has been proposed that uPAR forms cis-interactions with 
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integrins as associated proteins in lipid rafts and thereby transduces proliferative or 
migratory signals to cells upon binding of its ligand, uPA (192). Studies using resonance 
energy transfer microscopy and co-immunoprecipitation with purified recombinant 
proteins indicate that uPAR forms complexes with a subset of β1- and β2-integrins (193) 
and modulates the signaling capacity of these molecules (194). Based on these reports and 
our own studies, showing increased adhesion of fibroblasts to fibronectin after FXIIa 
stimulation, it was investigated whether fibronectin receptor α5β1-integrin influences 
FXIIa mitogenic activities. Pretreatment of lung fibroblasts with anti-α5- or anti-β1-
integrin blocking antibodies abolished [3H]-thymidine incorporation after exposure to 
FXIIa, while the IgG control antibody had no effect (Figure 4.16). This observation 
suggests that α5β1-integrin is involved in FXIIa-induced murine lung fibroblast 
proliferation. 
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Figure 4.15. uPAR is required for FXIIa mitogenic activities.  
(A) [3H]-thymidine incorporation in murine lung fibroblasts isolated from WT or uPAR deficient (uPAR-/-) 
mice after FXIIa (6 µg/ml) stimulation. Data represent mean values ± SD from three independent 
experiments, each performed in triplicate; ** p < 0.005; ANOVA, Tukey’s post test. NS, not significant. 
(B) Interaction of FXII with uPAR. Antibodies specific for uPAR were incubated with lysates from cells 
either stimulated or unstimulated with FXIIa (6 µg/ml) for 30 min. Immunocomplexes were precipitated 
using protein A-agarose beads and analyzed by Western blotting using antibodies against FXII. uPAR 
served as a loading control. IgG LCh, IgG light chain; IgG HCh, IgG heavy chain. Data are representative 
of three independent experiments.  
 
 
 
 47
Results 
________________________________________________________________________ 
 48
α-α5 integrin
* * *
0
900
600
300
1200
FXII
α-ß1 integrin
IgG
- + ++
+- - -
- - - +
D
N
A 
sy
nt
he
si
s
(c
pm
)
200
400
600
0
* * 
* * ** * *
FXII
IgG
- + ++
+- - -
- - - +
D
N
A 
sy
nt
he
si
s
(c
pm
)
D
N
A 
sy
nt
he
si
s
(c
pm
)
D
N
A 
sy
nt
he
si
s
(c
pm
)
D
N
A 
sy
nt
he
si
s
(c
pm
)
D
N
A 
sy
nt
he
si
s
(c
pm
)
 
A B 
Figure 4.16. α5β1-integrin regulates FXIIa-mediated murine lung fibroblast proliferation.  
(A) [3H]-thymidine incorporation in murine lung fibroblasts pretreated with (A) anti-β1- or (B) anti-α5-
integrin blocking antibodies (both diluted 1:200) or IgG isotype control (5 µg/ml) prior to FXIIa 
stimulation. Data represent mean values ± SD from three independent experiments, each performed in 
triplicate; *** p < 0.0005; ** p < 0.005; * p < 0.05; ANOVA, Tukey’s post test. 
 
4.6. TGF-1 regulates FXII expression in human lung 
fibroblasts 
 
4.6.1. TGF-1 upregulates FXII mRNA and protein levels in HLF 
 
Exposure of HLF to 10 ng/ml TGF-1 stimulated the synthesis of FXII in a time 
dependent manner. Real time analysis demonstrated the strongest induction of FXII 
mRNA expression 4 h after treatment (Fig. 4.17A). The maximal FXII protein level was 
achieved within a 48 h stimulation period and slightly declined over 72 h (Fig. 4.17B, C). 
Immunofluorescence staining revealed pronounced expression of FXII in response to 
TGF-1. FXII was detected on the cell surface (Fig. 4.17D, top panel), as well as in the 
cytoplasmic compartment of HLF (Fig. 4.17D, bottom panel). The purity of isolated HLF 
was verified by positive staining for fibronectin, vimentin, and collagen IV (Fig. 4.17E) 
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Figure 4.17. TGF-1 upregulates FXII expression in HLF. (A, B) Time course of FXII expression in 
HLF following TGF-1 stimulation as assessed by (A) real time PCR and (B) Western blotting. Real time 
PCR results are expressed as the fold-increase in FXII expression (normalized for -actin expression) 
versus values obtained for unstimulated cells, and are mean ± SD; n = 3; ** p < 0.01; ANOVA, Tukey’s 
post test. A representative blot out of three is illustrated. (C) Densitometric analysis of the blot presented in 
(B), ** p < 0.01; ANOVA, Tukey’s post test. (D) Immunofluorescence for the detection of FXII in 
unstimulated or TGF-1-treated HLF. Original magnification 40/1.25-0.75 oil-objective. Bar size 10 μm. 
(E) Immunofluorescence staining for fibronectin, vimentin, and collagen IV. Original magnification 
40/1.25-0.75 oil-objective. Bar size 10 μm.  
 
4.6.2. TGF-1 induces phosphorylation of MAPK, Akt and Smad3 
 
To dissect the contribution of different signal transduction pathways to TGF-1-
induced FXII production in HLF, MAPKs, Akt, and Smad phosphorylation kinetics in 
response to TGF-1 stimulation were analyzed. Phosphorylation of p44/42 and p38 
kinases reached a peak at 60 min and then gradually decreased. A marked increase in 
JNK activity was visible after 60 min, whereas enhanced phosphorylation of Akt was 
noted after 120 min (Fig. 4.18A). As expected, TGF-1 induced rapid phosphorylation of 
Smad 3 with maximal response within 30-60 min (Fig. 4.18B). No activation of c-jun was 
detected (data not shown). Immunofluorescence analysis demonstrated TGF-1 induced 
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translocation of phospho-Smad 3 to the nucleus (Fig. 4.18C). Accordingly increased 
levels of phospho-Smad 3 were observed in the nuclear extracts after TGF-1 treatment 
(Fig. 4.18D). Lamin B was used as a loading control and tubulin was used to assess the 
purity of the nuclear fraction. 
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Figure 4.18. TGF-1 induces phosphorylation of MAPK, Akt and Smad3. (A) HLF were treated for the 
indicated time points with TGF-1 and the activity and expression of p44/42, JNK, p38 and Akt kinases 
were analyzed by Western blotting. Phosphoproteins were detected via phospho-specific antibodies as 
indicated. Equal loading was confirmed via pan-specific antibodies. Data are representative of four 
independent experiments. (B) Western blot analysis of Smad 3 phosphorylation and expression in TGF-1 
stimulated HLF. Data are representative of four independent experiments. (C) TGF-1 dependent 
translocation of phospho-Smad 3 to the nucleus. HLF were incubated with TGF-1 for 1 h then washed, 
fixed and stained with phospho-Smad 3 antibody. Arrows indicate nuclear localisation of Smad 3. Original 
magnification 40/1.25-0.75 oil-objective. Bar size 10 μm. Data are representative of three independent 
experiments. (D) Western blot analysis of TGF-1 driven translocation of phospho-Smad 3 to the nucleus. 
HLF were treated for 1 h with TGF-1, nuclear extracts were prepared and immunoblotted with antibodies 
against phospho-Smad 3, lamin B, and tubulin. Lamin B was used as a loading control and tubulin was used 
to assess the purity of the nuclear fraction. Data are representative of three independent experiments.  
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4.6.3. Smad 3 and JNK kinase regulate TGF-1-induced FXII 
expression in HLF  
 
After determination of the phosphorylation kinetics, it was analyzed whether 
interference with these pathways would affect TGF-1-induced FXII expression in HLF. 
To address this, specific inhibitors of TRI, JNK, PI3K, MEK and p38 kinases 
(SB431542, SP600125, Wortmannin, PD98059, and SB203580, respectively) were used 
and their effect on TGF-1-stimulated expression of FXII was evaluated. As depicted in 
Fig. 4.19A, B, inhibition of TRI and JNK activity by SB431542 and SP600125, 
respectively, led to reduction of FXII expression in response to TGF-1. No change in 
FXII expression was visible when HLF were pretreated with inhibitors of Akt, MEK, and 
p38 kinases. To further confirm these results, HLF were transfected with JNK1- or Smad 
3-specific siRNAs, which caused significant knock-down of these proteins as 
demonstrated by Western blotting (Fig. 4.19C, D). As shown in Fig. 4.19E and G, knock-
down of JNK1 resulted in inhibition of FXII expression after TGF-1 stimulation. 
Similar results were obtained when Smad 3 was depleted (Fig. 4.19F, H). 
 
4.6.4. JNK kinase does not regulate Smad3 phosphorylation and 
translocation to the nucleus 
 
In next experiments the role of JNK kinase in Smad3 phosphorylation and 
translocation to the nucleus was investigated. Incubation of HLF with JNK inhibitor 
(SP600125) did not reduce Smad 3 phosphorylation, but completely abolished JNK 
activity (Fig. 4.20A). TRI inhibitor (SB431542) attenuated phosphorylation of Smad 3 
and JNK1 in response to TGF-β1, which indicated that phosphorylation of Smad 3 and 
JNK originates from TRI, the most proximal molecule in TGF-β1 signal transduction 
pathway (Fig. 4.20B). Furthermore, exposure of HLF to SP600125 had no effect on TGF-
β1-induced Smad 3 translocation to the nucleus, whereas SB431542 completely blocked 
this process (Fig. 4.20 C). Similar results were obtained by immunofluorescence analysis 
(Fig. 4.20D). SB431542 and SP600125 alone did not affect accumulation of Smad 3 in 
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the nucleus (data not shown). These results indicate that JNK kinase can regulate TGF-β1 
induced FXII expression in the absence of any effects on phosphorylation and 
translocation of Smad 3 to the nucleus.  
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Figure 4.19. Smad 3 and JNK kinase regulate TGF-1-induced FXII expression in HLF. (A) Western 
blot analysis of TGF-1-induced FXII expression in HLF. HLF were treated with SB431542, SP600125, 
Wortmannin (Wort), PD98059, or SB203580 for 1 h prior to incubation with TGF-1 for 48 h. Cell lysates 
were prepared and FXII expression was examined. -actin was used as a loading control. A representative 
blot out of three is illustrated. (B) Densitometric analysis of the blot presented in (A); ** p < 0.01; *** p < 
0.001; ANOVA, Tukey’s post test. (C, D) Determination of knockdown efficiency in HLF by siRNA 
transfection against (C) JNK1 or (D) Smad 3 by Western blotting. Data are representative of three 
independent experiments. (E, F) Effect of (E) JNK1 or (F) Smad 3 knockdown on TGF-1 induced FXII 
expression in HLF. Data are representative of three independent experiments. (G, H) Densytometric 
analysis of the blots presented in (E) and (F), respectively; * p < 0.05; ** p < 0.01, *** p < 0.001; ANOVA, 
Tukey’s post test. siR, scrumble siRNA; wort, wortmannin. 
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Figure 4.20. JNK1 kinase does not regulate Smad3 phosphorylation and translocation to the nucleus. 
(A, B) HLF were treated with TGF-1 in the absence or presence of (A) JNK inhibitor (SP600125) or (B) 
TRI inhibitor (SB431542), as indicated, and the activity and expression of Smad 3 and JNK were 
analyzed by Western blotting. Data are representative of four independent experiments. (C) Western blot 
analysis of TGF-1 driven translocation of phospho-Smad 3 to the nucleus. HLF were pretreated with 
SB431542 or SP600125 and then either unstimulated or stimulated for 1 h with TGF-1, nuclear extracts 
were prepared and immunoblotted with antibodies against phospho-Smad 3, lamin B, and tubulin. Lamin B 
was used as a loading control and tubulin was used to assess the purity of the nuclear fraction. Data are 
representative of three independent experiments. (D) TGF-1 driven translocation of phospho-Smad 3 to 
the nucleus. HLF were preincubated with SB431542 or SP600125 1 h prior to addition of TGF-1. After 1 
h the cells were washed, fixed and stained with phospho-Smad 3 antibody. Arrows indicate nuclear 
localisation of Smad 3. Original magnification 40/1.25-0.75 oil-objective. Bar size 10 μm. Data are 
representative of three independent experiments. 
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4.6.5. TGF-β1 induces FXII promoter activity via SBE located at 
position – 272 
 
To identify DNA elements required for TGF-β1-induced FXII production, NIH3T3 
cells were transiently transfected with a series of human FXII promoter deletion 
constructs (-1630 bp; -907 bp; -577 bp; -299 bp; Fig. 4.21A) and then luciferase activity 
in untreated and TGF-β1-treated cells was measured. NIH3T3 cells were used in these 
studies due to their high transfection efficiency. Cells transfected with pGL3-1630; 
pGL3-907; and pGL3-577 constructs displayed no increase in luciferase activity in 
response to TGF- β1, whereas strong induction of FXII promoter activity was observed in 
pGL3-299 transfected cells (Fig. 4.21B). These results indicate the presence of TGF-β1 
responsive element within -299/+1 bp in the human FXII promoter. In addition, the data 
suggest that repressor element(s) located in the region upstream of -299 bp may dampen 
the stimulatory effects of TGF- β1.  
To identify the TGF-β1-responsive element of the FXII promoter laying between -
299/+1 bp, this DNA region was examined for consensus SBEs. This analysis identified 
the putative SBE at position -272 bp (SBE-272, Fig. 4.21C). As expected, the point 
mutation of SBE-272 completely abolished FXII promoter activity in response to TGF-β1 
(Fig. 4.21D). To confirm these results, a construct lacking SBE-272 was generated (Fig. 
4.22A). The deletion of the sequence between -299 and -183 abrogated the ability of the 
FXII promoter to confer responsiveness to TGF-β1 (Fig. 4.22B).  
Next, the role of JNK/Smad 3 signaling pathways in the regulation of FXII 
expression was tested by a gene luciferase activity assay. The cells were transfected with 
a pGL3-299 construct, pretreated with indicated inhibitors, and then either unstimulated 
or stimulated with 10 ng/ml TGF-β1. As depicted in Fig. 4.22C TGF-β1 driven luciferase 
activity was strongly reduced only in the presence of SB431542 and SP600125 inhibitors. 
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Figure 4.21. TGF-β1 induces FXII promoter activity via SBE located at position – 272. (A) Schematic 
representation of FXII promoter deletion luciferase reporter constructs. Angled arrow indicates the 
transcription start site. (B) NIH3T3 cells were transfected with the indicated FXII promoter deletion 
constructs and then either unstimulated (white bars) or stimulated with TGF-1 (black bars). Luciferase 
activity was measured as described in “Materials and methods”. Data represent mean values ± SD from 
four independent experiments, each performed in triplicate; ** p < 0.01. (C) Schematic representation of 
the FXII promoter region containing putative SBE at position -272. pGL3-299 C/T represents a construct in 
which the SBE-272 was mutated by the replacement of C residue at position -273 by T. (D) NIH3T3 cells 
were transfected with the pGL3-299 or pGL3-299 C/T constructs. Luciferase activity was determined in 
untreated (white bars) and TGF-1-treated (black bars) cells. Data represent mean values ± SD from four 
independent experiments, each performed in triplicate; ** p < 0.01; ANOVA, Tukey’s post test.  
 
 
4.6.6. Smad 3 interacts with SBE-272 within the FXII promoter 
 
To examine the interaction of Smad 3 with SBE-272 ChIP and streptavidin pull-
down assays were performed. The ChIP assay clearly demonstrated TGF-β1-induced 
interaction of Smad 3 with the FXII promoter region (–299/+1 bp) flanking SBE-272 (Fig. 
4.23A). To further analyze the binding of Smad 3 to SBE-272, a streptavidin pull-down 
assay using biotinylated template spanning -283 and -258 bp region of FXII promoter 
was performed. As expected, Smad 3 was eluted from this template, whereas no 
interaction occurred when SBE-272 was mutated (Fig. 4.23B). These findings indicate that 
Smad 3 – SBE-272 form a complex after stimulation of HLF with TGF-β1. 
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Figure 4.22. TGF-β1 induces FXII promoter activity via SBE located at position – 272. 
(A) Schematic representation of pGL3-299 construct and a construct lacking SBE-272 (pGL3-183SBE-272). 
(B) NIH3T3 cells were transfected with pGL3-299 or pGL3-183SBE-272 and the luciferase activity was 
measured in unstimulated (white bars) and TGF-1 stimulated (black bars) cells. Data represent mean 
values ± SD from three independent experiments, each performed in triplicate; ** p < 0.01; ANOVA, 
Tukey’s post test. (C) NIH3T3 cells, transfected with pGL3-299 construct, were pretreated with SB431542, 
SP600125, Wortmannin (Wort), PD98059, or SB203580 for 1 h prior to incubation with TGF-1. 
Luciferase activity was determined in untreated (white bars) and TGF-1-treated (black bars) cells. Data 
represent mean values ± SD from three independent experiments, each performed in triplicate; * p < 0.05; 
** p < 0.01; *** p < 0.001; ANOVA, Tukey’s post test. 
 
4.6.7. JNK kinase affects binding of Smad 3 to SBE-272 
 
Since inhibition of JNK kinase did not have any impact on phosphorylation and 
translocation of Smad 3 to the nucleus, the involvement of this kinase in the formation of 
Smad 3 – SBE-272 complex was investigated by ChIP and streptavidin pull-down assays. 
HLF, pretreated with TRI or JNK1 inhibitors (SB431542 or SP600125, respectively), 
were either unstimulated or stimulated with TGF-β1, lysed, and a ChIP assay was 
performed using an anti-Smad3 antibody and an IgG isotype control. TGF-β1 induced 
Smad 3-DNA complex formation. This interaction was completely abolished when 
SB431542 was used, and dramatically reduced in the presence of SP600125 (Fig. 4.23C). 
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SB431542 and SP600125 alone did not affect interaction of Smad3 with DNA (data not 
shown). Similar results were obtained when the streptavidin pull-down assay was 
performed (Fig. 4.23D). 
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Figure 4.23. Smad 3 - SBE-272 interaction is suppressed in the presence of JNK inhibitor. (A) HLF 
were either unstimulated or stimulated with TGF-1 and ChIP analysis was performed using a Smad 3 
antibody or an isotype IgG control. PCR was performed with immunoprecipitated DNA as described in 
“Materials and methods”. PCR products were separated by agarose gel electophoresis and detected by 
staining with ethidium bromide. Data are representative of three independent experiments. (B) Nuclear 
extracts from untreated or TGF-1-treated cells were incubated with biotinylated templates (SBE-283/-258 or 
SBE-283/-258 C/T) and Smad 3 was detected by Western blotting. Data are representative of three independent 
experiments. (C) HLF were pretreated with SB431542 or SP600125 for 1 h prior to incubation with TGF-
1. ChIP analysis was performed using Smad 3 antibody or isotype IgG control. PCR was performed with 
immunoprecipitated chromatin as described in “Materials and methods”. Data are representative of three 
independent experiments. (D) HLF were preincubated with SB431542 or SP600125 for 1 h prior to 
addition of TGF-1. Nuclear extracts were prepared and then incubated with a biotinylated template (SBE-
283/-258). Smad 3 was detected by Western blotting. Data are representative of three independent 
experiments. 
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5. Discussion 
 
5.1. Expression of FXII, FXI and HMWK is elevated in lung 
fibrosis 
It is well known that components of the coagulation and fibrinolysis pathways play 
important roles in the processes of tissue injury and repair (195). Coagulation 
mechanisms are activated at sites of inflammation, and extravascular fibrin formation 
commonly occurs at foci of tissue injury (196). There is accumulating evidence that 
increased expression and activation of the extrinsic coagulation pathway play 
pathophysiological roles in numerous disease settings, including acute and chronic lung 
injury (174). 
To determine the potential role of the intrinsic coagulation pathway in human 
fibrotic lung disease, expression of FXII, FXI and HMWK in the lungs of patients with 
established IPF was examined. The expression of these factors on mRNA and the protein 
level was markedly elevated in IPF lung specimens, particularly from microdissected 
fibrotic regions. To identify the cell populations in the lung which contribute to increased 
content of FXII, FXI and HMWK in the alveolar compartment, the mRNA levels in ATII 
cells and lung fibroblasts were characterized. FXII expression in lung fibroblasts from 
IPF lungs was upregulated, while FXII mRNA was not detected in ATII cells. The 
regulation of FXII expression in lung fibroblasts will be discussed later. FXI and HMWK 
mRNA were expressed by lung fibroblasts and ATII cells. Neither fibroblasts nor ATII 
cells derived from IPF patients showed altered mRNA levels of FXI and HMWK. The 
lack of significant change in FXI and HMWK mRNA level in ATII and lung fibroblasts 
suggests that other cell populations, such as type I alveolar epithelial cells, alveolar 
macrophages or bronchial epithelial cells, may contribute to increased expression of FXI 
and HMWK in fibrotic lungs. 
The presence of coagulation factors in the alveolar space in fibrotic lungs may also 
result from plasma spill-over through a leaky vessel barrier. Presented data give evidence 
that, next to the systemic circulation and the vascular bed, the resident lung cells are also 
capable of providing high amounts of FXII, FXI and HMWK. It has been generally 
accepted that the contact phase components are produced mainly by hepatocytes, and 
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then secreted into the blood stream. Nevertheless, FXI has been reported to be 
synthesized in the kidney and in the lung at a relatively high level in comparison to the 
liver. HMWK mRNA has been already detected in the kidney, pancreas, placenta and 
heart (149). The results showed that the lung is a source of intrinsic coagulation pathway 
factors as well. Similarly, extrinsic coagulation factors, namely TF and FX, have been 
found to be expressed in the lung. Different inflammatory cytokines and profibrotic 
growth factors are known to stimulate the expression of TF by several cell types, which 
leads to extrinsic coagulation pathway activation outside the blood stream (197,198). 
Animal studies employing inhalative bleomycin administration demonstrated that 
alveolar macrophages and – to a lesser extent – ATII cells are the main sources of locally 
produced TF in response to lung injury (199). FX was reported to be synthesized by 
human and murine fibroblasts in the areas of fibrotic lung tissue (200).  
The enhanced procoagulant activity in BAL fluid in IPF patients has been attributed 
to increased expression of TF, which leads to extrinsic coagulation pathway activation 
and fibrin accumulation in the alveolar space (174). Similarly, this study showed the 
activation of the intrinsic coagulation pathway in the alveolar compartment of IPF 
patients due to increased FXII activity in the BAL fluid. Activation of FXII at this 
location may contribute to a procoagulatory state in IPF lungs through FXI activation, 
which results in fibrin formation in the lungs.  
Elevated expression of FXII, FXI and HMWK in lung homogenate of IPF patients 
corresponds to their altered expression observed in the animal model of bleomycin-
induced lung fibrosis. mRNA and protein levels of intrinsic coagulation pathway factors 
were increased at day 4 and 21 after bleomycin administration. The first week after 
bleomycin application is characterized by a strong inflammatory response, therefore the 
elevated expression of intrinsic blood coagulation factors at day 4 may result from 
microvascular leakage which occurs at this phase. From the second week onwards, 
inflammation is dramatically reduced and the fibrotic pathway takes over (171). The 
elevated mRNA and protein levels of FXI, FXII and HMWK at day 21 post bleomycin 
application suggest that resident lung cells may contribute to the synthesis of these 
factors. Moreover, murine fibroblasts and ATII cells were found to produce FXI and 
HMWK. In contrast to results in human lungs, FXII mRNA was detected neither in 
 59
Discussion 
________________________________________________________________________ 
murine lung fibroblasts nor in ATII cells. Therefore, it would be of interest to examine 
other cell types as a potential source of FXII production in murine lungs.  
The activation of extrinsic coagulation pathways in fibrotic lungs has been reported 
to promote fibrin deposition and fibroproliferative processes. The present study 
demonstrates that the intrinsic coagulation pathway is activated in IPF lungs as well and 
may be involved in disease development. Furthermore, the evidence that resident lung 
cells are able to produce intrinsic coagulation pathway components was provided. 
However, the regulation of cell-specific expression and the contribution of the intrinsic 
coagulation system to pathomechanisms of lung fibrosis need further investigation. 
 
5.2. Inhibition of FXIIa or knockout of FXII protects against 
lung fibrosis 
 
Coagulation FXII is a serine protease that is capable of initiating blood coagulation 
under certain conditions. Upon binding to negatively charged surfaces, FXII becomes 
converted into a FXIIa, which exhibits serine protease-type activity in its carboxyl-
terminal domain. FXIIa converts FXI to FXIa and PK into KLK. Consequently, FXI 
activation culminates in a series of proteolytic reactions, which results in thrombin 
generation and subsequent clot formation. The activation of KLK by FXII leads to BK 
generation and activation of fibrinolytic system. In the present study, it was hypothesized 
that increased expression and activation of FXII promote lung fibrosis. To prove this 
hypothesis, lung fibrosis in FXII-/- mice was induced by intratracheal administration of 
bleomycin. Characterization of the late fibrotic response to bleomycin injury revealed that 
total lung collagen accumulation was attenuated in FXII-/- mice compared to WT animals. 
Severe fibrosis after bleomycin instillation was strongly reduced in FXII-/- mice and the 
survival of FXII-/- mice was significantly improved.  
FXIIa activates FXI, which leads to thrombin and fibrin generation. Thus, FXII 
deficiency might result in impaired fibrin generation due to lack of FXI activation. To 
investigate this possibility fibrin staining in FXII-/- and WT mice was performed. Fibrin 
accumulation in the fibrotic regions of lungs after bleomycin instillation was comparable 
in WT and FXII-/- mice. These findings indicate that FXII deficiency did not affect fibrin 
generation in bleomycin-injured lung tissue. These data suggest that the extrinsic 
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coagulation pathway accounts for fibrin deposition in lung tissue. Additionally, fibrin 
deposition in injured lungs of FXII-/- mice may result from activation of FXI by thrombin 
in the absence of FXII.  
The strong reduction of lung fibrosis in FXII-/- mice suggests that the application of 
FXIIa inhibitor may have beneficial effects as a treatment in lung fibrosis. To reveal this 
hypothesis CTI, a specific FXIIa inhibitor, was administered intratracheally to 
bleomycin-treated mice. The application of CTI was found to improve survival, to reduce 
collagen content and to preserve lung structure after bleomycin challenge. The significant 
decrease in the grade of lung fibrosis in mice treated with CTI compared with mice 
treated with saline provides evidence of the possible therapeuthic outcome of CTI in 
experimental fibrosis.  
The exact mechanism of FXIIa inhibition by CTI, a 12 kDa polypeptide derived 
from corn seeds, is not known. Intratracheal administration of CTI seems to have side 
effects as an influx of inflammatory cells to the alveolar compartment in the control 
animals was noticed after CTI instillation. Observed side effects may result from the 
activation of immune response by CTI and may restrict therapeutic application of this 
inhibitor in the treatment of lung fibrosis. These findings led to the administration of 
another FXIIa inhibitor, PCK, to bleomycin-treated mice. PCK is the active-site-directed 
inhibitor of FXIIa and KLK (93,94). PCK was administered intratracheally and showed 
no side effects in the control animals which received saline instead of bleomycin. 
However, PCK instillation failed to attenuate the development of lung fibrosis in 
bleomycin-treated animals. The discrepancy between results obtained with CTI and PCK 
inhibitor could be related to the ability of PCK to block KLK activity. The role of KLK in 
the development of lung fibrosis has never been studied. KLK is an activator of u-PA and 
therefore may potentiate plasmin formation. It is possible that the inhibition of KLK 
activity promotes fibrosis development by attenuation of fibrinolysis and by potentiation 
of fibrin deposition in the lungs. The dosis of PCK used in our study might be too low to 
inhibit FXII activity in the lung and to limit the fibrotic response. Studies with a higher 
PCK dose would be required to determine PCK effects on the development of bleomycin-
induced lung fibrosis.  
In conclusion, the findings of the present study suggest that FXIIa inhibition has a 
therapeutic influence on lung fibrosis development. Multitargeting anticoagulants, such 
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as warfarin and unfractioned heparin or inhibition of FXIa, are associated with the risk of 
bleeding complications. Taking into consideration that FXII deficient patients have no 
bleeding disorders, therapeutic approaches for lung fibrosis based on FXIIa inhibition 
may be beneficial and free of bleeding complications.  
 
5.3. FXII-induced proliferation of murine lung fibroblasts may 
contribute to lung fibrosis development 
 
The altered alveolar haemostatic system may contribute to the pathogenesis of 
fibrotic lung diseases by other mechanisms than fibrin generation. This observation is 
evidenced by a recent report, which showed that pulmonary fibrosis develops in 
fibrinogen-null mice after bleomycin administration. Besides their role in fibrin formation 
FXa and the TF-FVIIa complex exhibit cellular activities that contribute to the 
development of lung fibrosis. Thrombin and FXa stimulate fibroblast proliferation, 
procollagen production and the expression of profibrotic and proinflammatory cytokines 
(183-186). 
Different mechanisms may explain FXII-associated profibrotic activities. Firstly, 
FXII may potentiate alveolar procoagulant activities by FXIa generation which leads to 
fibrin formation. Nevertheless, the physiological role of FXII in haemostasis is 
questioned, since FXII deficient patients have no bleeding disorders. Reports showing 
that FXI can be activated independently of FXII by thrombin (18) suggest that FXII 
promotes lung fibrosis by a mechanism independent of its procoagulant activities. 
Finally, activation of the extrinsic coagulation pathway has been observed in alveolar 
compartments of fibrotic lungs. The results presented indicate that the role of FXII in the 
development of lung fibrosis is not necessarily related to its procoagulant activities. 
FXII displays a wide variety of important functions apart from its ability to 
generate FXIa. First of all, FXIIa initiates KLK activation, which leads to BK formation. 
BK exhibits proinflammatory and vasodilatory activities by two G-protein-coupled 
receptors, designated B1 and B2 (60). To evaluate the functional role of BK in the 
development of bleomycin-induced lung injury, mice lacking both BK receptors (B1B2-/-) 
were treated with bleomycin. Similarly to WT animals, B1B2-/- mice developed strong 
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fibrosis after bleomycin instillation, as demonstrated by morphological analysis and 
compliance measurements. These results clearly demonstrate that BK and its receptors do 
not play a pivotal role in bleomycin-induced lung fibrosis and do not mediate FXII 
profibrotic effects.  
Interestingly, besides its role in the activation of the intrinsic coagulation pathway 
and the KLK-kinin system, FXII exhibits mitogenic activities. FXII/FXIIa has been 
reported to stimulate proliferation of some cell types in a MAPK/ERK-dependent 
manner. The physiological significance of FXII-induced cell proliferation is unknown. 
Mitogenic activities of FXII may play a role in fetal lung and liver development, since 
fetal hepatocytes and fetal ATII cells were found to responsd to FXII/FXIIa (90). 
Additionally, FXII may be involved in vessel formation since it increases proliferation of 
smooth muscle cells and endothelial cells (90).  
Intensive proliferation of fibroblasts and their differentiation into myofibroblats is a 
hallmark of IPF (151). These observations raise the possibility that FXII may contribute 
to the development of lung fibrosis by stimulating proliferation of lung fibroblasts. In line 
with this consideration, an increase in lung fibroblast proliferation after exposure to 
FXIIa was observed. The concentration of FXII required to induce cell proliferation (3-6 
µg/ml) was below FXII plasma concentration. These results strongly suggest that FXIIa 
potentiates lung fibrosis via stimulation of lung fibroblast proliferation. Similarly, other 
coagulation proteases such as thrombin and FXa stimulate fibroblast proliferation in a 
PAR-1-dependent manner (184,185). A potential role of FX- and thrombin-induced 
fibroblast proliferation in lung fibrosis is further underscored by the recent finding that 
PAR-1 deficient mice are protected against bleomycin-induced lung fibrosis (188).  
The involvement of the p44/42 signaling pathway in FXII-induced cell proliferation 
has already been reported. The results of the present study demonstrate that exposure of 
murine lung fibroblasts to FXIIa leads to rapid activation of various kinases including 
p44/42, Akt, and p38 in murine lung fibroblasts. The data demonstrated that p44/42 
activation was essential for FXIIa mitogenic activities since PD98059 attenuated 
proliferation of lung fibroblasts after FXIIa stimulation. The blockade of PI3K and p38 
kinases did not affect the induction of DNA synthesis by FXIIa, which indicates that 
activation of these kinases is not required for the enhancement of lung fibroblast 
proliferation by FXIIa. 
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The FXII receptor which would be able to transduce mitogenic activities is not 
known. Interestingly, FXII has been reported to assemble on the endothelial cell surface 
through a multiprotein complex consisting of gC1qR, uPAR and CK1 (83). uPAR has 
been showed to play a role in a number of biological processes including pericellular 
proteolysis, inflammation, angiogenesis, matrix remodelling during wound healing, 
tumor invasion or metastasis (201). The cellular responses activated by binding of u-PA 
to uPAR require transmembrane signaling. Since uPAR has no intracellular domain, 
uPAR responses are mediated by direct contacts of uPAR with a variety of extracellular 
proteins and membrane receptors, such as integrins, EGF receptor, caveolin and others. 
As a result of these interactions, uPAR triggers the activation of signaling pathways such 
as tyrosine- and serine-protein kinases, Src, focal adhesion kinase (FAK), Rac, 
ERK/MAPK and JAK/STAT pathways. uPAR has been reported to mediate FXII growth 
factor activities towards endothelial cells (191). The results indicate an essential role of 
uPAR in FXII-induced proliferation of primary murine lung fibroblasts as well. The 
increase in cell proliferation after exposure to FXIIa was blocked by an anti-uPAR 
blocking antibody and peptides corresponding to a sequence of uPAR in domain 2. 
Additionally, murine lung fibroblasts deficient in uPAR did not respond to FXIIa 
stimulation. Moreover, in immunoprecipitation studies, interaction between uPAR and 
FXIIa was demonstrated. Collectively, to the best of my knowledge for the first time, the 
interaction of FXIIa with uPAR on the surface of murine lung fibroblasts was evidenced.  
Since uPAR has no kinase activity and does not directly interact with intracellular 
pathways, further studies were designed to determine the mechanism for outside-in 
signaling triggered by FXIIa. The presented studies showed that blocking antibodies 
against β1- and α5- integrins attenuated FXII–induced proliferation of murine lung 
fibroblasts. This finding indicates that α5β1-integrin is required for FXIIa mitogenic 
activities. Presumably, FXIIa-induced proliferation may occur as a consequence of FXIIa 
binding to uPAR, the subsequent binding of FXII/uPAR complex to α5β1-integrin and 
signal transduction through α5β1-integrin. Similarly, uPA binding to its receptor on the 
Chinese hamster ovary cell surface has been reported to trigger uPAR binding to α5β1-
integrin, and subsequent cell adhesion and migration (202). Further investigations using 
immunoprecipitation studies are needed to define possible interactions sites between 
uPAR and α5β1-integrin after exposure to FXIIa. 
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It would be of interest to determine whether the FXII mitogenic activity depends on 
FXII proteolytic activity. Although CTI, the specific FXIIa inhibitor, was shown to block 
FXII mitogenic function, the precise mechanism of FXII inhibition by CTI is not 
characterized. CTI binds both FXII and FXIIa and probably blocks FXII activity by 
changing its conformation. The altered conformation of FXII might interfere with FXII 
binding to uPAR. Therefore, further studies conducting other FXII inhibitors and FXIIa 
blocking antibodies are needed to clarify the role of FXII protease activity in the 
regulation of cell proliferation. 
The presented data strongly suggest that FXIIa-induced proliferation may play a 
role in the development of bleomycin-induced lung fibrosis. The findings are supported 
by reports which show that other coagulations factors, namely FX and TF, act as 
mitogens for lung fibroblasts. Moreover, inhibition of FXII by CTI and FXII-deficiency 
attenuated bleomycin-induced pulmonary fibrosis in mice. Thus, strategies aimed at 
blocking FXII mitogenic activity in fibrotic lung disease may represent new treatment 
opportunities. Further studies focusing on the molecular mechanism responsible for the 
growth factor-like function of FXII are necessary to design novel approaches to inhibit 
the profibrotic effects of FXII without compromising blood coagulation. 
 
5.4. Regulation of FXII expression in human lung fibroblasts 
 
Factor XII is believed to participate in a number of physiologial processes including 
inflammation, coagulation and fibrinolysis (60). The previous reports demonstrated that 
FXII is mainly produced by the liver and its expression is regulated by estrogen (203). 
The FXII promoter contains an ERE that mediates 17 estradiol-stimulated induction of 
FXII gene expression (143-145). Moreover, HAE type III, characterized by increased 
activity of FXII, appears to be correlated with high estrogen levels (104). 
Since the expression of FXII was also documented in other organs such as the lung 
and the placenta (149), the present study elucidates FXII production in the lung and the 
molecular mechanism underlying the regulation of its sythesis in primary human lung 
fibroblasts (HLF). It was demonstrated, to the best of my knowledge for the first time, 
that FXII is produced by HLF and that its expression is controlled by TGF-β1. Moreover, 
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the requirement of JNK and Smad3 signaling pathways for TGF-β1 driven FXII synthesis 
in HLF was shown. The present results are supported by a recent report showing the 
importance of JNK kinase in TGF-β1 induced expression of connective tissue growth 
factor (CTGF) in HLF (204). 
The involvement of different signaling components, including p44/42, Akt, p38, and 
JNK, in the transcriptional induction of TGF-β1 target genes has already been 
demonstrated. TGF-β1-mediated activation of p38 kinase was found to be essential for 
mammary epithelial cell apoptosis, although it was not sufficient for the epithelial to 
mesenchymal transdifferentiation (205). Involvement of p44/42 and Akt signaling 
pathways has been implicated in TGF-β1 driven induction of PAI-1 expression in 
endothelial and mesangial cells, respectively (206,207). The present study demonstrates 
that the blockade of p44/42, Akt, p38 kinases did not affect the induction of FXII 
expression by TGF-β1, indicating that activation of these kinases is not essential for the 
enhancement of FXII expression in HLF. The crucial role of JNK kinase is further 
confirmed by a luciferase reporter assay, where preincubation of HLF with JNK specific 
inhibitor (SP600125) completely abolished TGF-β1 stimulated FXII promoter activity. 
Surprisingly, JNK activity was not required for Smad 3 phosphorylation and translocation 
to the nucleus in response to TGF-β1. The presented study is in contrast to previously 
published data demonstrating TGF-β induced JNK-dependent phosphorylation of Smad 3 
and its accumulation in the nucleus (208). The reason for this discrepancy is not clear; 
however, some differences in the experimental procedure, such as a choice of cell type, 
may be of importance. The lack of any impact of JNK kinase on Smad 3 phosphorylation 
and translocation to the nucleus indicates that this kinase may target other transcription 
factors/coactivators which, together with Smad 3, could regulate FXII transcription. To 
support this hypothesis, a strong reduction of Smad 3-DNA complex formation was noted 
when HLF were preincubated with SP600125 prior to addition of TGF-β1. Several 
transcription factors/coactivators, such as AP-1 (209), Sp-1 (210), IRF-7 (211) or 
CBP/p300 (212), were found to be able to interact with Smad molecules, therefore it is 
well imaginable that JNK kinase may control interaction of Smad 3 with other proteins 
and thus enhance TGF-β1 mediated FXII production. The role of p44/42 and Akt kinases 
in the modulation of DNA binding activities and transcriptional potential has already 
been demonstrated in other systems (207,213,214). Therefore, further efforts are needed 
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to clarify the composition of transcriptional machinery which is responsible for TGF- β1-
induced FXII expression in HLF.  
TGF-1 induction of FXII gene transcription was further investigated by the 
generation of a series of FXII promoter luciferase reporter constructs. Transient 
transfection of NIH3T3 cells with these constructs revealed the requirement of the 
sequence spanning -299 and +1 bp for TGF-β1 driven FXII expression. Further analysis 
of this promoter region demonstrated the presence of the SBE containing the consensus 
sequence at position -272. This is in line with previously published reports showing the 
interaction of the MH1 domain of receptor associated Smad or common-mediator Smad 
with G/C rich sequences of DNA, termed CAGA boxes (215,216). The mutation or 
deletion of SBE-272 further underscored its importance for the TGF-β1 mediated FXII 
expression in HLF. In addition, using several independent approaches, direct interaction 
of Smad 3 with SBE-272 was demonstrated. Interestingly, lower TGF-1 inducibility was 
observed when longer portions of FXII promoter  were studied indicating the presence of 
repressor element(s) located upstream of -299 bp, a fact that is common to other inducible 
promoters as well (217). In agreement with this contention, the basal luciferase activity of 
the pGL3-299 construct was also elevated. Detailed studies are required to map the 
specific repressor binding sequence(s) within the FXII promoter.  
The TGF-1-induced expression of FXII may play a potentially important role in 
haemostasis and cell functions under various pathophysiological conditions. TGF-1 is a 
multifunctional cytokine that is critically involved in several disease states, particularly in 
fibrosis of the lung (159,218), kidney (219,220) and liver (221). Recent studies suggest 
that induction of TF (160) and PAI-1 (222-224) by TGF-1 may play a crucial role in the 
profibrotic action of this growth factor. In lung fibrosis severe alterations of the alveolar 
haemostatic balance favouring extravascular pulmonary fibrin accumulation have been 
observed. Increased alveolar procoagulant and antifibrinolytic activities under these 
conditions have been attributed to TF/FVII-induced activation of the extrinsic coagulation 
cascade and increased PAI-1 expression (162,174). Moreover, fibroblasts have been 
identified as an important cellular source of TGF-1 mediated TF (160) and PAI-1 
expression (225). This study adds relevant information in this regard since it 
demonstrates that TGF-1 can induce expression of FXII in HLF as well. Thus, not only 
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proteins belonging to the extrinsic coagulation cascade but also those of the contact phase 
may well contribute to the shift in the alveolar haemostatic balance and subsequent fibrin 
accumulation in the injured lung. In line with these considerations, presented data 
indicate that proteins of the contact phase are highly expressed in lungs of patients with 
IPF. Furthermore, the presently described induction of FXII by TGF-1 may well 
contribute to other pathological conditions which have been linked to TGF-1 mediated 
alterations in the coagulation and fibrinolysis systems, such as obesity (198) and insulin 
resistance (226), neovascular ocular diseases (227) or peritoneal adhesion formation 
(228-230).  
This study demonstrates that FXII acts as a novel mitogen for murine lung 
fibroblasts. Elevated expression of TGF-β1 in lungs of IPF patients may potentiate 
synthesis of FXII by lung fibroblasts. Consequently, FXII may stimulate proliferation of 
lung fibroblasts and subsequently promote the development of lung fibrosis. Thus, FXII 
mitogenic activities toward lung fibroblasts could mediate and enhance the 
fibroproliferative effects of TGF-β1. Therefore, understanding the mechanisms regulating 
the expression of FXII will be of importance to inhibit lung fibrosis and other fibrotic 
disorders. Moreover, it has been shown that FXII may exhibit growth factor activities 
towards HepG2 cells, aortic smooth muscle cells, epithelioid carcinoma cells (A431), 
bovine newborn aortic endothelial cells, fetal hepatocytes or ATII pneumocytes (90,91). 
Therefore, in addition to its role in the haemostatic system, FXII may act as a signaling 
molecule for other growth factor-sensitive cells to regulate cell growth, proliferation, 
and/or differentiation processes under physiological as well as pathological conditions.  
In conclusion, the presented results demonstrate that TGF-β1-induced FXII 
production in HLF is mediated by JNK and Smad 3 signaling pathways. Moreover, SBE 
at position -272 bp within FXII promoter was identified and the importance of JNK 
activity in the Smad 3 – DNA complex formation was showed. These findings provide 
new insights into the molecular mechanism responsible for the regulation of FXII 
expression in HLF and implicate its possible role in IPF, characterized by elevated TGF-
1 levels and disregulated haemostasis.  
The present study demonstrated increased expression of FXII in the lungs of IPF 
patients and bleomycin challenged mice. Furthermore, FXIIa was identified as a novel 
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mitogenic factor for murine lung fibroblasts. It was found that treatment of HLF with 
TGF-β increases FXII expression. Thus, elevated level of TGF-β1 in fibrotic lungs may 
cause the upregulation of FXII expression in IPF lungs. FXII may contribute to increased 
proliferation of lung fibroblasts and subsequently to the development of pulmonary 
fibrosis (Figure 5.1). Thus, FXII and its downstream signaling pathway in lung 
fibroblasts should be considered as a novel target for therapeutic interventions in 
pulmonary fibrosis. 
 
 
 
 
 
Figure 5.1. Factor XIIa may contribute to increased proliferation of fibroblasts in lung fibrosis. 
Conclusions 
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6. Conclusions  
 
Activation of the coagulation cascade is a feature of a number of lung diseases 
associated with inflammation and excessive deposition of extracellular matrix proteins, 
including lung fibrosis (174,231). IPF is a respiratory disorder caused by lung injury, 
increased proliferation of mesenchymal cells and excessive accumulation of extracellular 
matrix proteins in the lung (151). Although the primary function of the blood coagulation 
cascade is to preserve haemostasis and to prevent blood loss in case of tissue injury, 
uncontrolled activation of the blood coagulation cascade contributes to 
pathophysiological conditions including chronic lung injury. The extrinsic blood 
coagulation factors, notably TF and FVII, have been implicated in the pathogenesis of 
pulmonary fibrosis (174). Nevertheless, the potential role of FXII, the key intrinsic 
coagulation pathway factor, has never been reported in the pathomechanisms of lung 
fibrosis.  
The aim of this study was to examine the contribution of intrinsic coagulation 
components to the development of pulmonary fibrosis. Increased expression of FXII, FXI 
and HMWK and elevated activity of FXII in the lungs of bleomycin-treated mice and IPF 
patients were noted. Moreover, the results provide evidence that FXII, FXI and HMWK 
are locally produced in the injured lungs. The study demonstrated that FXII, a central 
protease of the intrinsic coagulation cascade, has a capacity to drive fibrotic responses to 
lung injury, since knockout of FXII in mice or inhalative application of a specific FXIIa 
inhibitor attenuated bleomycin-induced lung fibrosis as evidenced by reduced collagen 
deposition and decreased mortality. The findings reported in the present study 
demonstrate for the first time a potential role of FXII during the fibrotic phases of 
experimentally induced lung injury. The evidence that targeting FXIIa may be of 
potentional therapeutic interest was herein provided.  
Finally, it was demonstrated that FXIIa mitogenic activities may be responsible for 
FXII profibrotic activities. The results showed that FXIIa induces lung fibroblast 
proliferation via activation of the ERK 1/2. This effect required 1- and α5-integrins, 
uPAR, since the blockade of 1- and α5-integrin or the knockout of uPAR abolished 
FXIIa mitogenic activities. Moreover, FXII-dependent induction of lung fibroblast 
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proliferation was attenuated by a pharmacological blockade of the ERK 1/2 pathway and 
by a FXIIa specific inhibitor, CTI.  
In addition, FXII promoter studies demonstrated that FXII expression in HLF was 
regulated by TGF-β1, a potent profibrotic cytokine upregulated in IPF lungs. The 
presented findings demonstrated that TGF-β1-induced FXII production in HLF is 
mediated by JNK and Smad 3 signaling pathways. Moreover, SBE at position -272 bp 
within the FXII promoter was identified and the importance of JNK activity in the Smad 
3 – DNA complex formation was shown. The findings provide new insights into the 
molecular mechanism responsible for regulation of FXII expression in HLF and implicate 
its possible role in lung fibrosis, which is characterized by elevated TGF-1 levels and 
dysregulated haemostasis. 
In conclusion, this study provides evidence of a possible role of FXII in 
development of fibrotic lung diseases. Strategies aimed at blocking FXII in fibrotic lung 
disease may represent new treatment opportunities. 
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